

Customer No. 20350
TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200

Attorney Docket No. 18623-134-1
Client Ref No. EPI 0134.10US

ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
Washington, D.C. 20231

"Express Mail" Label No. EL104193879US
Date of Deposit: November 10, 1998

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

By: 

Sir:

Transmitted herewith for filing is the

- ☐ patent application of
- ☐ continuation patent application of
- ☐ divisional patent application of
- ☒ continuation-in-part patent application of

Inventor(s)/Applicant Identifier: Alessandro Sette, John Sidney, W. Martin Kast, and Scott Southwood

For: HLA BINDING PEPTIDES AND THEIR USES

☒ This application claims priority from each of the following Application Nos./filing dates:

USSN 08/205,713, filed March 4, 1994

the disclosure(s) of which is (are) incorporated by reference.

☐ Please amend this application by adding the following before the first sentence: "This application is a ☐ continuation ☐ continuation-in-part of application No. _____, filed _____ which are incorporated herein by reference for all purposes."

Enclosed are:

☐ _____ sheet(s) of ☐ formal ☐ informal drawing(s).

☐ An assignment of the invention to _____

☒ A ☐ signed ☒ unsigned Declaration & Power of Attorney

A ☐ signed ☐ unsigned Declaration.

A Power of Attorney.

A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 ☐ is enclosed ☐ was filed in the prior application and small entity status is still proper and desired.

☐ A certified copy of a _____ application.

☐ Information Disclosure Statement under 37 CFR 1.97.

☐ A petition to extend time to respond in the parent application.

☐ Notification of change of ☐ power of attorney ☐ correspondence address filed in prior application.


☐

In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(b),
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:
(415) 576-0200

Facsimile:
(415) 576-0300


Ellen Lauver Weber
Reg No.: 32,762
Attorneys for Applicant

PATENT APPLICATION

HLA BINDING PEPTIDES AND THEIR USES

Inventor(s):

Alessandro Sette, an Italian citizen
5551 Linda Rosa Avenue
La Jolla, CA 92037

John Sidney, a U.S. citizen
8541 D. Villa La Jolla Drive
La Jolla, CA 92037

W. Martin Kast, a citizen of The Netherlands
Maria Rutgersweg106
Leiden, The Netherlands 2331 NX

Scott Southwood, a U.S. citizen
10679 Strathmore Dr.
Santee, CA 92071

Assignee:

Epimmune, Inc.
San Diego, CA 92121

TOWNSEND AND TOWNSEND AND CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
(415)576-0200

HLA BINDING PEPTIDES AND THEIR USES

REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of USSN 08/205,713 filed March 4, 1994. The present application is also related to USSN 09/017,735, USSN 08/753,622, USSN 08/822,382, USSN 60/013,980, USSN 08/589,108, USSN 08/454,033, USSN 08/349,177, USSN 08/073,205, and USSN 08/027,146. The present application is also related to USSN 09/017,524, USSN 08/821,739, USSN 60/013,833, USSN 08/758,409, USSN 08/589,107, USSN 08/451,913 and to USSN 08/347,610, USSN 08/186,266, USSN 08/159,339, USSN 09/116,061, USSN 08/103,396, USSN 08/027,746, and USSN 07/926,666. The present application is also related to USSN 09/017,743; USSN 08/753,615; USSN 08/590,298; USSN 08/452,843; USSN 09/115,400; USSN 08/344,824; and USSN 08/278,634. The present application is also related to USSN 08/197,484 and USSN 08/815,396. All of the above applications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

The present invention relates to compositions and methods for preventing, treating or diagnosing a number of pathological states such as viral diseases and cancers. In particular, it provides novel peptides capable of binding selected major histocompatibility complex (MHC) molecules and inducing an immune response.

MHC molecules are classified as either Class I or Class II molecules. Class II MHC molecules are expressed primarily on cells involved in initiating and sustaining immune responses, such as T lymphocytes, B lymphocytes, macrophages, etc. Class II MHC molecules are recognized by helper T lymphocytes and induce proliferation of helper T lymphocytes and amplification of the immune response to the particular immunogenic peptide that is displayed. Class I MHC molecules are expressed on almost all nucleated cells and are recognized by cytotoxic T lymphocytes (CTLs), which then destroy the antigen-bearing cells. CTLs are particularly important in tumor rejection and in fighting viral infections.

The CTL recognizes the antigen in the form of a peptide fragment bound to the MHC class I molecules rather than the intact foreign antigen itself. The antigen must normally be endogenously synthesized by the cell, and a portion of the protein

antigen is degraded into small peptide fragments in the cytoplasm. Some of these small peptides translocate into a pre-Golgi compartment and interact with class I heavy chains to facilitate proper folding and association with the subunit $\beta 2$ microglobulin. The peptide-MHC class I complex is then routed to the cell surface for expression and potential recognition by specific CTLs.

Investigations of the crystal structure of the human MHC class I molecule, HLA-A2.1, indicate that a peptide binding groove is created by the folding of the $\alpha 1$ and $\alpha 2$ domains of the class I heavy chain (Bjorkman et al., Nature 329:506 (1987). In these investigations, however, the identity of peptides bound to the groove was not determined.

Buus et al., Science 242:1065 (1988) first described a method for acid elution of bound peptides from MHC. Subsequently, Rammensee and his coworkers (Falk et al., Nature 351:290 (1991) have developed an approach to characterize naturally processed peptides bound to class I molecules. Other investigators have successfully achieved direct amino acid sequencing of the more abundant peptides in various HPLC fractions by conventional automated sequencing of peptides eluted from class I molecules of the B type (Jardetzky, et al., Nature 353:326 (1991) and of the A2.1 type by mass spectrometry (Hunt, et al., Science 225:1261 (1992). A review of the characterization of naturally processed peptides in MHC Class I has been presented by Rötzschke and Falk (Rötzschke and Falk, Immunol. Today 12:447 (1991).

Sette et al., Proc. Natl. Acad. Sci. USA 86:3296 (1989) showed that MHC allele specific motifs could be used to predict MHC binding capacity. Schaeffer et al., Proc. Natl. Acad. Sci. USA 86:4649 (1989) showed that MHC binding was related to immunogenicity. Several authors (De Bruijn et al., Eur. J. Immunol., 21:2963-2970 (1991); Pamer et al., 991 Nature 353:852-955 (1991)) have provided preliminary evidence that class I binding motifs can be applied to the identification of potential immunogenic peptides in animal models. Class I motifs specific for a number of human alleles of a given class I isotype have yet to be described. It is desirable that the combined frequencies of these different alleles should be high enough to cover a large fraction or perhaps the majority of the human outbred population.

Despite the developments in the art, the prior art has yet to provide a useful human peptide-based vaccine or therapeutic agent based on this work. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION

The present invention provides compositions comprising immunogenic peptides having binding motifs for HLA-A2.1 molecules. The immunogenic peptides, which bind to the appropriate MHC allele, are preferably 9 to 10 residues in length and
 5 comprise conserved residues at certain positions such as positions 2 and 9. Moreover, the peptides do not comprise negative binding residues as defined herein at other positions such as positions 1, 3, 6 and/or 7 in the case of peptides 9 amino acids in length and positions 1, 3, 4, 5, 7, 8 and/or 9 in the case of peptides 10 amino acids in length. The present invention defines positions within a motif enabling the selection of peptides
 10 which will bind efficiently to HLA A2.1.

The motifs of the inventions include peptide of 9 amino acids which have a first conserved residue at the second position from the N-terminus selected from the group consisting of I, V, A and T and a second conserved residue at the C-terminal position selected from the group consisting of V, L, I, A and M. Alternatively, the
 15 peptide may have a first conserved residue at the second position from the N-terminus selected from the group consisting of L, M, I, V, A and T; and a second conserved residue at the C-terminal position selected from the group consisting of A and M. If the peptide has 10 residues it will contain a first conserved residue at the second position from the N-terminus selected from the group consisting of L, M, I, V, A, and T; and a second
 20 conserved residue at the C-terminal position selected from the group consisting of V, I, L, A and M; wherein the first and second conserved residues are separated by 7 residues.

Epitopes on a number of immunogenic target proteins can be identified using the peptides of the invention. Examples of suitable antigens include prostate cancer specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B core and
 25 surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV1), Kaposi's sarcoma herpes virus (KSHV), human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53 and murine p53 (mp53), CEA, trypanosome surface antigen (TSA), members of the tyrosinas related protein (TRP) families, and Her2/neu. The peptides are thus useful in
 30 pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

The present invention also provides compositions comprising immunogenic peptides having binding motifs for MHC Class I molecules. The

immunogenic peptides are typically between about 8 and about 11 residues and comprise conserved residues involved in binding proteins encoded by the appropriate MHC allele. A number of allele specific motifs have been identified.

For instance, the motif for HLA-A3.2 comprises from the N-terminus to
 5 C-terminus a first conserved residue of L, M, I, V, S, A, T and F at position 2 and a second conserved residue of K, R or Y at the C-terminal end. Other first conserved residues are C, G or D and alternatively E. Other second conserved residues are H or F. The first and second conserved residues are preferably separated by 6 to 7 residues.

The motif for HLA-A1 comprises from the N-terminus to the C-terminus a
 10 first conserved residue of T, S or M, a second conserved residue of D or E, and a third conserved residue of Y. Other second conserved residues are A, S or T. The first and second conserved residues are adjacent and are preferably separated from the third conserved residue by 6 to 7 residues. A second motif consists of a first conserved residue of E or D and a second conserved residue of Y where the first and second conserved
 15 residues are separated by 5 to 6 residues.

The motif for HLA-A11 comprises from the N-terminus to the C-terminus a first conserved residue of T, V, M, L, I, S, A, G, N, C D, or F at position 2 and a C-terminal conserved residue of K, R, Y or H. The first and second conserved residues are preferably separated by 6 or 7 residues.

20 The motif for HLA-A24.1 comprises from the N-terminus to the C-terminus a first conserved residue of Y, F or W at position 2 and a C terminal conserved residue of F, I, W, M or L. The first and second conserved residues are preferably separated by 6 to 7 residues.

Epitopes on a number of potential target proteins can be identified in this
 25 manner. Examples of suitable antigens include prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, malignant melanoma antigen (MAGE-1) Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV1), papilloma virus antigens, Lassa virus, mycobacterium tuberculosis (MT), p53 and murine p53 (mp53), CEA, and
 30 Her2/neu, and members of the tyrosinase related protein (TRP) families. The peptides are thus useful in pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

The present invention also provides compositions comprising immunogenic peptides having binding motifs for non-A HLA alleles. The immunogenic peptides are preferably about 9 to 10 residues in length and comprise conserved residues at certain positions such as proline at position 2 and an aromatic residue (e.g., Y, W, F) or hydrophobic residue (e.g., L, I, V, M, or A) at the carboxy terminus. In particular, an advantage of the peptides of the invention is their ability to bind to two or more different HLA alleles.

Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, malignant melanoma antigen (MAGE-1) Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV1), papilloma virus antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, and Her2/neu. The peptides are thus useful in pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

Definitions

The term "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of adjacent amino acids. The oligopeptides of the invention are less than about 15 residues in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues.

An "immunogenic peptide" is a peptide which comprises an allele-specific motif such that the peptide will bind an MHC molecule and induce a CTL response. Immunogenic peptides of the invention are capable of binding to an appropriate HLA-A2.1 molecule and inducing a cytotoxic T cell response against the antigen from which the immunogenic peptide is derived.

Immunogenic peptides are conveniently identified using the algorithms of the invention. The algorithms are mathematical procedures that produce a score which enables the selection of immunogenic peptides. Typically one uses the algorithmic score with a "binding threshold" to enable selection of peptides that have a high probability of binding at a certain affinity and will in turn be immunogenic. The algorithm is based upon either the effects on MHC binding of a particular amino acid at a particular position

of a peptide or the effects on binding of a particular substitution in a motif containing peptide.

A "conserved residue" is an amino acid which occurs in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide. Typically a conserved residue is one where the MHC structure may provide a contact point with the immunogenic peptide. At least one to three or more, preferably two, conserved residues within a peptide of defined length defines a motif for an immunogenic peptide. These residues are typically in close contact with the peptide binding groove, with their side chains buried in specific pockets of the groove itself. Typically, an immunogenic peptide will comprise up to three conserved residues, more usually two conserved residues.

As used herein, "negative binding residues" are amino acids which if present at certain positions (for example, positions 1, 3 and/or 7 of a 9-mer) will result in a peptide being a nonbinder or poor binder and in turn fail to be immunogenic i.e. induce a CTL response.

The term "motif" refers to the pattern of residues in a peptide of defined length, usually about 8 to about 11 amino acids, which is recognized by a particular MHC allele. The peptide motifs are typically different for each human MHC allele and differ in the pattern of the highly conserved residues and negative residues.

The binding motif for an allele can be defined with increasing degrees of precision. In one case, all of the conserved residues are present in the correct positions in a peptide and there are no negative residues in positions 1,3 and/or 7.

The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the peptides of this invention do not contain materials normally associated with their in situ environment, e.g., MHC I molecules on antigen presenting cells. Even where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated peptides of this invention do not contain such endogenous co-purified protein.

The term "residue" refers to an amino acid or amino acid mimetic incorporated in an oligopeptide by an amide bond or amide bond mimetic.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. HLA-A2.1 Motif

The present invention relates to the determination of allele-specific peptide motifs for human Class I MHC (sometimes referred to as HLA) allele subtypes, in particular, peptide motifs recognized by HLA-A2.1 alleles. These motifs are then used to define T cell epitopes from any desired antigen, particularly those associated with human viral diseases, cancers or autoimmune diseases, for which the amino acid sequence of the potential antigen or autoantigen targets is known.

Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu.

Peptides comprising the epitopes from these antigens are synthesized and then tested for their ability to bind to the appropriate MHC molecules in assays using, for example, purified class I molecules and radioiodinated peptides and/or cells expressing empty class I molecules by, for instance, immunofluorescent staining and flow microfluorometry, peptide-dependent class I assembly assays, and inhibition of CTL recognition by peptide competition. Those peptides that bind to the class I molecule are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with virally infected target cells or tumor cells as potential therapeutic agents.

The MHC class I antigens are encoded by the HLA-A, B, and C loci. HLA-A and B antigens are expressed at the cell surface at approximately equal densities, whereas the expression of HLA-C is significantly lower (perhaps as much as 10-fold lower). Each of these loci have a number of alleles. The peptide binding motifs of the invention are relatively specific for each allelic subtype.

For peptide-based vaccines, the peptides of the present invention preferably comprise a motif recognized by an MHC I molecule having a wide distribution in the human population. Since the MHC alleles occur at different frequencies within different ethnic groups and races, the choice of target MHC allele may depend upon the

target population. Table 1 shows the frequency of various alleles at the HLA-A locus products among different races. For instance, the majority of the Caucasoid population can be covered by peptides which bind to four HLA-A allele subtypes, specifically HLA-A2.1, A1, A3.2, and A24.1. Similarly, the majority of the Asian population is

5 encompassed with the addition of peptides binding to a fifth allele HLA-A11.2.

TABLE 1

A Allele/Subtype	N(69)*	A(54)	C(502)
A1	10.1(7)	1.8(1)	27.4(138)
A2.1	11.5(8)	37.0(20)	39.8(199)
A2.2	10.1(7)	0	3.3(17)
A2.3	1.4(1)	5.5(3)	0.8(4)
A2.4	-	-	-
A2.5	-	0	0.2(0)
A3.1	1.4(1)	5.5(3)	21.5(108)
A3.2	5.7(4)	5.5(3)	0
A11.1	0	31.4(17)	8.7(44)
A11.2	5.7(4)	3.7(2)	0
A11.3	0	-	3.9(20)
A23	4.3(3)	27.7(15)	15.3(77)
A24	2.9(2)	-	-
A24.2	-	-	-
A24.3	-	-	6.9(35)
A25	1.4(1)	9.2(5)	5.9(30)
A26.1	4.3(3)	-	1.0(5)
A26.2	7.2(5)	-	-
A26V	-	3.7(2)	1.6(8)
A28.1	10.1(7)	-	7.5(38)
A28.2	1.4(1)	-	1.4(7)
A29.1	1.4(1)	-	5.3(27)
A29.2	10.1(7)	1.8(1)	4.9(25)
A30.1	8.6(6)	-	0.2(1)
A30.2	1.4(1)	-	3.9(20)
A30.3	7.2(5)	-	6.9(35)
A31	4.3(3)	7.4(4)	7.1(36)
A32	2.8(2)	-	2.5(13)
Aw33.1	8.6(6)	-	1.2(6)
Aw33.2	2.8(2)	16.6(9)	-
Aw34.1	1.4(1)	-	0.8(4)
Aw34.2	14.5(10)	-	-
Aw36	5.9(4)	-	-

Table compiled from B. DuPont, Immunobiology of HLA, Vol. I, Histocompatibility Testing 1987, Springer-Verlag, New York 1989.

5

* N - negroid; A = Asian; C = Caucasoid. Numbers in parenthesis represent the number of individuals included in the analysis.

The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid

structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids having D-forms is represented by a lower case single letter or a lower case three letter symbol. Glycine has no asymmetric carbon atom and is simply referred to as "Gly" or G.

The procedures used to identify peptides of the present invention generally follow the methods disclosed in Falk et al., Nature 351:290 (1991), which is incorporated herein by reference. Briefly, the methods involve large-scale isolation of MHC class I molecules, typically by immunoprecipitation or affinity chromatography, from the appropriate cell or cell line. Examples of other methods for isolation of the desired MHC molecule equally well known to the artisan include ion exchange chromatography, lectin chromatography, size exclusion, high performance ligand chromatography, and a combination of all of the above techniques.

In the typical case, immunoprecipitation is used to isolate the desired allele. A number of protocols can be used, depending upon the specificity of the antibodies used. For example, allele-specific mAb reagents can be used for the affinity purification of the HLA-A, HLA-B1, and HLA-C molecules. Several mAb reagents for the isolation of HLA-A molecules are available. The monoclonal BB7.2 is suitable for isolating HLA-A2 molecules. Affinity columns prepared with these mAbs using standard techniques are successfully used to purify the respective HLA-A allele products.

In addition to allele-specific mAbs, broadly reactive anti-HLA-A, B, C mAbs, such as W6/32 and B9.12.1, and one anti-HLA-B, C mAb, B1.23.2, could be used in alternative affinity purification protocols as described in previous applications.

The peptides bound to the peptide binding groove of the isolated MHC molecules are eluted typically using acid treatment. Peptides can also be dissociated from class I molecules by a variety of standard denaturing means, such as heat, pH, detergents, salts, chaotropic agents, or a combination thereof.

Peptide fractions are further separated from the MHC molecules by reversed-phase high performance liquid chromatography (HPLC) and sequenced. Peptides can be separated by a variety of other standard means well known to the artisan, including filtration, ultrafiltration, electrophoresis, size chromatography, precipitation with specific antibodies, ion exchange chromatography, isoelectrofocusing, and the like.

Sequencing of the isolated peptides can be performed according to standard techniques such as Edman degradation (Hunkapiller, M.W., et al., Methods Enzymol. 91, 399 [1983]). Other methods suitable for sequencing include mass spectrometry sequencing of individual peptides as previously described (Hunt, et al.,
 5 Science 225:1261 (1992), which is incorporated herein by reference). Amino acid sequencing of bulk heterogeneous peptides (e.g., pooled HPLC fractions) from different class I molecules typically reveals a characteristic sequence motif for each class I allele.

Definition of motifs specific for different class I alleles allows the identification of potential peptide epitopes from an antigenic protein whose amino acid
 10 sequence is known. Typically, identification of potential peptide epitopes is initially carried out using a computer to scan the amino acid sequence of a desired antigen for the presence of motifs. The epitopic sequences are then synthesized. The capacity to bind MHC Class molecules is measured in a variety of different ways. One means is a Class I molecule binding assay as described in the related applications, noted above. Other
 15 alternatives described in the literature include inhibition of antigen presentation (Sette, et al., J. Immunol. 141:3893 (1991), in vitro assembly assays (Townsend, et al., Cell 62:285 (1990), and FACS based assays using mutated cells, such as RMA.S (Melief, et al., Eur. J. Immunol. 21:2963 (1991)).

Next, peptides that test positive in the MHC class I binding assay are
 20 assayed for the ability of the peptides to induce specific CTL responses in vitro. For instance, antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells (Inaba, et al., J. Exp. Med. 166:182 (1987); Boog, Eur. J. Immunol. 18:219 [1988]).

Alternatively, mutant mammalian cell lines that are deficient in their
 25 ability to load class I molecules with internally processed peptides, such as the mouse cell lines RMA-S (Kärre, et al., Nature, 319:675 (1986); Ljunggren, et al., Eur. J. Immunol. 21:2963-2970 (1991)), and the human somatic T cell hybrid, T-2 (Cerundolo, et al., Nature 345:449-452 (1990)) and which have been transfected with the appropriate human
 30 class I genes are conveniently used, when peptide is added to them, to test for the capacity of the peptide to induce in vitro primary CTL responses. Other eukaryotic cell lines which could be used include various insect cell lines such as mosquito larvae (ATCC cell lines CCL 125, 126, 1660, 1591, 6585, 6586), silkworm (ATTC CRL 8851), armyworm

(ATCC CRL 1711), moth (ATCC CCL 80) and *Drosophila* cell lines such as a Schneider cell line (see Schneider *J. Embryol. Exp. Morphol.* 27:353-365 [1927]).

Peripheral blood lymphocytes are conveniently isolated following simple venipuncture or leukapheresis of normal donors or patients and used as the responder cell sources of CTL precursors. In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100 μ M of peptide in serum-free media for 4 hours under appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the responder cell populations *in vitro* for 7 to 10 days under optimized culture conditions. Positive CTL activation can be determined by assaying the cultures for the presence of CTLs that kill radiolabeled target cells, both specific peptide-pulsed targets as well as target cells expressing the endogenously processed form of the relevant virus or tumor antigen from which the peptide sequence was derived.

Specificity and MHC restriction of the CTL is determined by testing against different peptide target cells expressing appropriate or inappropriate human MHC class I. The peptides that test positive in the MHC binding assays and give rise to specific CTL responses are referred to herein as immunogenic peptides.

The immunogenic peptides can be prepared synthetically, or by recombinant DNA technology or from natural sources such as whole viruses or tumors. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments or particles.

The polypeptides or peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

Desirably, the peptide will be as small as possible while still maintaining substantially all of the biological activity of the large peptide. When possible, it may be desirable to optimize peptides of the invention to a length of 9 or 10 amino acid residues, commensurate in size with endogenously processed viral peptides or tumor cell peptides that are bound to MHC class I molecules on the cell surface.

Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e.g., improved pharmacological characteristics, while

increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell. For instance, the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding. By conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. The effect of single amino acid substitutions may also be probed using D-amino acids. Such modifications may be made using well known peptide synthesis procedures, as described in e.g., Merrifield, Science 232:341-347 (1986), Barany and Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp. 1-284 (1979); and Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984), incorporated by reference herein.

The peptides can also be modified by extending or decreasing the compound's amino acid sequence, e.g., by the addition or deletion of amino acids. The peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e.g., those at critical contact sites or conserved residues, may generally not be altered without an adverse effect on biological activity. The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L- α -amino acids, or their D-isomers, but may include non-natural amino acids as well, such as β - γ - δ -amino acids, as well as many derivatives of L- α -amino acids.

Typically, a series of peptides with single amino acid substitutions are employed to determine the effect of electrostatic charge, hydrophobicity, etc. on binding. For instance, a series of positively charged (e.g., Lys or Arg) or negatively charged (e.g., Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards various MHC molecules and T cell receptors. In addition, multiple substitutions using small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues may be employed. The substitutions may be homo-oligomers or hetero-oligomers. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased binding affinity

for an MHC molecule or T cell receptor may also be achieved by such substitutions, compared to the affinity of the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.

- 5 Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 2 when it is desired to finely modulate
- 10 the characteristics of the peptide.

TABLE 2

<u>Original Residue</u>	<u>Exemplary Substitution</u>
Ala	Ser
Arg	Lys, His
Asn	Gln
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Pro
His	Lys; Arg
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; His
Met	Leu; Ile
Phe	Tyr; Trp
Ser	Thr
Thr	Ser
Trp	Tyr; Phe
Tyr	Trp; Phe
Val	Ile; Leu

Pro

Gly

Substantial changes in function (e.g., affinity for MHC molecules or T cell receptors) are made by selecting substitutions that are less conservative than those in

5 Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which (a) 10 hydrophilic residue, e.g. seryl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (c) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

15 The peptides may also comprise isosteres of two or more residues in the immunogenic peptide. An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence because the steric conformation of the first sequence fits a binding site specific for the second sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art. Such 20 modifications include modifications of the amide nitrogen, the α -carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, peptides and Proteins, Vol. VII (Weinstein ed., 1983).

25 Modifications of peptides with various amino acid mimetics or unnatural amino acids are particularly useful in increasing the stability of the peptide in vivo. Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokin. 11:291-302 (1986). Half life of the peptides of the present invention is conveniently determined using a 25% human 30 serum (v/v) assay. The protocol is generally as follows. Pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At

predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloroacetic acid or ethanol. The cloudy reaction sample is cooled (4°C) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability-specific chromatography conditions.

The peptides of the present invention or analogs thereof which have CTL stimulating activity may be modified to provide desired attributes other than improved serum half life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Particularly preferred immunogenic peptides/T helper conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. Alternatively, the CTL peptide may be linked to the T helper peptide without a spacer.

The immunogenic peptide may be linked to the T helper peptide either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated. Exemplary T helper peptides include tetanus toxoid 830-843, influenza 307-319, malaria circumsporozoite 382-398 and 378-389.

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes CTL. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the alpha and epsilon amino groups of a Lys residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment a particularly effective immunogen comprises palmitic acid attached to alpha and epsilon amino groups

of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P₃CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide. See, Deres et al., Nature 342:561-564 (1989), incorporated herein by reference. Peptides of the invention can be coupled to P₃CSS, for example, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Further, as the induction of neutralizing antibodies can also be primed with P₃CSS conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to more effectively elicit both humoral and cell-mediated responses to infection.

In addition, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support, or larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide. Modification at the C terminus in some cases may alter binding characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH₂ acylation, e.g., by alkanoyl (C₁-C₂₀) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

The peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co. (1984), supra.

Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al., Molecular Cloning. A Laboratory Manual,

Cold Spring Harbor Press, Cold Spring Harbor, New York (1982), which is incorporated herein by reference. Thus, fusion proteins which comprise one or more peptide sequences of the invention can be used to present the appropriate T cell epitope.

As the coding sequence for peptides of the length contemplated herein can
5 be synthesized by chemical techniques, for example, the phosphotriester method of
Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981), modification can be made simply
by substituting the appropriate base(s) for those encoding the native peptide sequence.
The coding sequence can then be provided with appropriate linkers and ligated into
expression vectors commonly available in the art, and the vectors used to transform
10 suitable hosts to produce the desired fusion protein. A number of such vectors and
suitable host systems are now available. For expression of the fusion proteins, the coding
sequence will be provided with operably linked start and stop codons, promoter and
terminator regions and usually a replication system to provide an expression vector for
expression in the desired cellular host. For example, promoter sequences compatible with
15 bacterial hosts are provided in plasmids containing convenient restriction sites for
insertion of the desired coding sequence. The resulting expression vectors are
transformed into suitable bacterial hosts. Of course, yeast or mammalian cell hosts may
also be used, employing suitable vectors and control sequences.

The peptides of the present invention and pharmaceutical and vaccine
20 compositions thereof are useful for administration to mammals, particularly humans, to
treat and/or prevent viral infection and cancer. Examples of diseases which can be treated
using the immunogenic peptides of the invention include prostate cancer, hepatitis B,
hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV and
condyloma acuminatum.

25 For pharmaceutical compositions, the immunogenic peptides of the
invention are administered to an individual already suffering from cancer or infected with
the virus of interest. Those in the incubation phase or the acute phase of infection can be
treated with the immunogenic peptides separately or in conjunction with other treatments,
as appropriate. In therapeutic applications, compositions are administered to a patient in
30 an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and
to cure or at least partially arrest symptoms and/or complications. An amount adequate to
accomplish this is defined as "therapeutically effective dose." Amounts effective for this
use will depend on, e.g., the peptide composition, the manner of administration, the stage

and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0 μg to about 5000 μg of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0 μg to about 1000 μg of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

For therapeutic use, administration should begin at the first sign of viral infection or the detection or surgical removal of tumors or shortly after diagnosis in the case of acute infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses followed by boosting doses may be required.

Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals. For those individuals susceptible (or predisposed) to developing chronic infection the compositions are particularly useful in methods for preventing the evolution from acute to chronic infection. Where the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.

The peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eliminate virus-infected cells in carriers. It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate a cytotoxic T cell response. Thus, for treatment of chronic infection, a representative dose is in the range of about 1.0 μg to about 5000 μg , preferably about 5 μg to 1000 μg for a 70 kg patient per dose. Immunizing doses followed by boosting doses at established intervals, e.g., from one to four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue

until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of CTL stimulatory peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or targeted selectively to infected cells, as well as increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where

the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g.,

5 liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, incorporated herein by reference.

For targeting to the immune cells, a ligand to be incorporated into the

10 liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

15 For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as

20 those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant

25 must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute

30 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

In another aspect the present invention is directed to vaccines which contain as an active ingredient an immunogenically effective amount of an immunogenic peptide as described herein. The peptide(s) may be introduced into a host, including humans, linked to its own carrier or as a homopolymer or heteropolymer of active peptide units. Such a polymer has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the virus or tumor cells. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are materials well known in the art. And, as mentioned above, CTL responses can be primed by conjugating peptides of the invention to lipids, such as P3CSS. Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen, and the host becomes at least partially immune to later infection, or resistant to developing chronic infection.

Vaccine compositions containing the peptides of the invention are administered to a patient susceptible to or otherwise at risk of viral infection or cancer to elicit an immune response against the antigen and thus enhance the patient's own immune response capabilities. Such an amount is defined to be an "immunogenically effective dose." In this use, the precise amounts again depend on the patient's state of health and weight, the mode of administration, the nature of the formulation, etc., but generally range from about 1.0 μg to about 5000 μg per 70 kilogram patient, more commonly from about 10 μg to about 500 μg mg per 70 kg of body weight.

In some instances it may be desirable to combine the peptide vaccines of the invention with vaccines which induce neutralizing antibody responses to the virus of interest, particularly to viral envelope antigens.

For therapeutic or immunization purposes, nucleic acids encoding one or more of the peptides of the invention can also be administered to the patient. A number

of methods are conveniently used to deliver the nucleic acids to the patient. For instance, the nucleic acid can be delivered directly, as "naked DNA". This approach is described, for instance, in Wolff *et al.*, *Science* 247: 1465-1468 (1990) as well as U.S. Patent Nos. 5,580,859 and 5,589,466. The nucleic acids can also be administered using ballistic

5 delivery as described, for instance, in U.S. Patent No. 5,204,253. Particles comprised solely of DNA can be administered. Alternatively, DNA can be adhered to particles, such as gold particles. The nucleic acids can also be delivered complexed to cationic compounds, such as cationic lipids. Lipid-mediated gene delivery methods are described, for instance, in WO 96/18372; WO 93/24640; Mannino and Gould-Fogerite (1988)

10 *BioTechniques* 6(7): 682-691; Rose U.S. Pat No. 5,279,833; WO 91/06309; and Felgner *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414. The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into an acutely or

15 chronically infected host or into a noninfected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits a host CTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848, incorporated herein by reference. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover *et al.* (*Nature* 351:456-460

20 (1991)) which is incorporated herein by reference. A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g., *Salmonella* typhi vectors and the like, will be apparent to those skilled in the art from the description herein.

A preferred means of administering nucleic acids encoding the peptides of

25 the invention uses minigene constructs encoding multiple epitopes of the invention. To create a DNA sequence encoding the selected CTL epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes are reverse translated. A human codon usage table is used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences are directly adjoined, creating a continuous polypeptide

30 sequence. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequence that could be reverse translated and included in the minigene sequence include: helper T lymphocyte epitopes, a leader (signal) sequence, and an endoplasmic reticulum retention signal. In

addition, MHC presentation of CTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL epitopes.

The minigene sequence is converted to DNA by assembling
 5 oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides are joined using T4 DNA ligase. This synthetic minigene, encoding the CTL epitope polypeptide, can then be cloned into a desired expression vector.

10 Standard regulatory sequences well known to those of skill in the art are included in the vector to ensure expression in the target cells. Several vector elements are required: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an *E. coli* origin of replication; and an *E. coli* selectable marker (e.g. ampicillin or kanamycin resistance).
 15 Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene
 20 expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences can also be considered for increasing minigene expression. It has recently been proposed that immunostimulatory sequences (ISSs or CpGs) play a role in the immunogenicity of DNA vaccines. These sequences could be included in the vector,
 25 outside the minigene coding sequence, if found to enhance immunogenicity.

In some embodiments, a bioisotonic expression vector, to allow production of the minigene-encoded epitopes and a second protein included to enhance or decrease immunogenicity can be used. Examples of proteins or polypeptides that could
 30 beneficially enhance the immune response if co-expressed include cytokines (e.g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e.g. LeIF) or costimulatory molecules. Helper (HTL) epitopes could be joined to intracellular targeting signals and expressed separately from the CTL epitopes. This would allow direction of the HTL epitopes to a cell compartment different than the CTL epitopes. If required, this could facilitate more

efficient entry of HTL epitopes into the MHC class II pathway, thereby improving CTL induction. In contrast to CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF- β) may be beneficial in certain diseases.

- 5 Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis.
- 10 Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

- Therapeutic quantities of plasmid DNA are produced by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate fermentation medium (such as Terrific Broth), and grown to saturation in shaker flasks or
- 15 a bioreactor according to well known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by Quiagen. If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

- Purified plasmid DNA can be prepared for injection using a variety of
- 20 formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). A variety of methods have been described, and new techniques may become available. As noted above, nucleic acids are conveniently formulated with cationic lipids. In addition, glycolipids, fusogenic liposomes, peptides and compounds referred to collectively as protective, interactive, non-condensing (PINC)
- 25 could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

- Target cell sensitization can be used as a functional assay for expression and MHC class I presentation of minigene-encoded CTL epitopes. The plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL
- 30 chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell

sorting (FACS). These cells are then chromium-51 labeled and used as target cells for epitope-specific CTL lines. Cytolysis, detected by ^{51}Cr release, indicates production of MHC presentation of minigene-encoded CTL epitopes.

In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human MHC molecules are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g. IM for DNA in PBS, IP for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for 1 week in the presence of peptides encoding each epitope being tested. These effector cells (CTLs) are assayed for cytolysis of peptide-loaded, chromium-51 labeled target cells using standard techniques. Lysis of target cells sensitized by MHC loading of peptides corresponding to minigene-encoded epitopes demonstrates DNA vaccine function for *in vivo* induction of CTLs.

Antigenic peptides may be used to elicit CTL ex vivo, as well. The resulting CTL, can be used to treat chronic infections (viral or bacterial) or tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a peptide vaccine approach of therapy. Ex vivo CTL responses to a particular pathogen (infectious agent or tumor antigen) are induced by incubating in tissue culture the patient's CTL precursor cells (CTLp) together with a source of antigen-presenting cells (APC) and the appropriate immunogenic peptide. After an appropriate incubation time (typically 1-4 weeks), in which the CTLp are activated and mature and expand into effector CTL, the cells are infused back into the patient, where they will destroy their specific target cell (an infected cell or a tumor cell).

The peptides may also find use as diagnostic reagents. For example, a peptide of the invention may be used to determine the susceptibility of a particular individual to a treatment regimen which employs the peptide or related peptides, and thus may be helpful in modifying an existing treatment protocol or in determining a prognosis for an affected individual. In addition, the peptides may also be used to predict which individuals will be at substantial risk for developing chronic infection.

The following example is offered by way of illustration, not by way of limitation.

EXAMPLE 1

Class I antigen isolation was carried out as described in the related applications, noted above. Naturally processed peptides were then isolated and sequenced as described there. An allele-specific motif and algorithms were determined and quantitative binding assays were carried out.

Using the motifs identified above for the HLA-A2.1 allele amino acid sequences from a number of antigens were analyzed for the presence of these motifs. Table 3 provides the results of these searches. The letter "J" represents norleucine.

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

Table 3

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
17.0317	9	LQIGNIISI	Flu.24	0.0130
38.0103	9	NLSLSCHAA	CEA.432	0.0110
1233.11	9	YLSGANLNV	CEA.605V9	0.0690
1295.03	9	SMPPPGTRV	p53.149M2	0.0290
1295.04	9	SLPPPGTRV	p53.149L2	0.0410
1317.24	9	KTCPVQLWV	p53.139	0.0069
1323.02	9	KLLPENNVV	p53.24V9	0.0130
1323.04	9	ALNKMFBQV	p53.129B7V9	0.0260
1323.06	9	KLBPVQLWV	p53.139L2B3	0.1100
1323.08	9	BLTIHYNVY	p53.229B1L2V9	0.0430
1323.18	10	LLPPQHLIRV	p53.188L2	0.0061
1323.29	11	YMCNSSCMGGM	p53.236	0.0075
1323.31	11	YLCNSSCMGGV	p53.236L2V11	0.2300
1323.34	11	KLYQGSYGFRV	p53.101L2V11	0.0620
1324.07	9	CQLAKTCPV	p53.135	0.0240
1325.01	9	RLPEAAPPV	p53.65L2	0.0640
1325.02	9	GLAPPQHLV	p53.187V9	0.0130
1325.04	9	KMAELVHFL	MAGE3.112M2	0.2100

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
1325.05	9	KLAELVHFL	MAGE3.112L2	0.2500
1326.01	9	CLLAKTCPV	p53.135L2	0.0400
1326.02	9	KLSQHMTEV	p53.164L2	0.0410
1326.04	9	ELAPVVAPV	p53.68L2V9	0.0860
1326.06	10	QLAKTCPVQV	p53.136	0.0320
1326.08	9	HLTEVVRRV	p53.168L2	0.0180
1329.01	11	KTYQGSYGFR		0.0028
1329.03	10	VVVPYEPPEV	p53.216	0.0081
1329.14	9	BQLAKTBPV	p53.135B1B7	0.0490
1329.15	9	BLLAKTBPV	p53.135B1L2B7	0.1100
1330.01	9	QIIGYVIGT	CEA.78	0.0160
1330.02	9	QLIGYVIGV	CEA.78L2V9	0.5300
1330.05	9	YVCGIQNSV	CEA.569	0.0510
1330.06	9	YLCGIQNSV	CEA.569L2	0.1000
1330.07	9	ATVGIMIGV	CEA.687	0.1400
1330.08	9	ALVGIMIGV	CEA.687L2	0.5000
1330.09	10	VLYGPDDPTI	CEA.411	0.0170
1330.10	10	VLYGPDDPTV	CEA.411V10	0.0310
1331.02	9	DLMLSPDDV	p53.42V9	
1331.03	9	ALMLSPDDI	p53.42A1	
1331.04	9	ALMLSPDDV	p53.42A1V9	
1331.05	9	DLMLSPADI	p53.42A7	
1331.06	9	DLMLSPADV	p53.42A7V9	
1331.07	9	DLMLSPDAI	p53.42A8	
1331.08	9	DLMLSPDAV	p53.42A8V9	
38.0007	9	AILTFGSFV	KSHV.89	0.0850
38.0009	9	HLRDFALAV	KSHV.106	0.0183
38.0015	9	ALLGSIAL	KSHV.155	0.0470
38.0018	9	ALLATILAA	KSHV.161	0.0490
38.0019	9	LLATILAAV	KSHV.162	0.1600
38.0022	9	RLFADELAA	KSHV.14	0.0150

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
38.0024	9	YLSKCTLAV	KSHV.65	0.2000
38.0026	9	LVYHIYSKI	KSHV.153	0.0457
38.0029	9	SMYLCILSA	KSHV.208	0.0250
38.0030	9	YLCILSALV	KSHV.210	0.3500
38.0033	9	VMFSYLQSL	KSHV.268	0.5000
38.0035	9	RLHVVYAYSA	KSHV.285	0.0270
38.0039	9	GLQTLGAFV	KSHV.98	0.0110
38.0040	9	FVEEQMTWA	KSHV.105	0.0380
38.0041	9	QMTWAQTVV	KSHV.109	0.0110
38.0042	9	IILDTAIFV	KSHV.130	0.6800
38.0043	9	AIFVCNAFV	KSHV.135	0.0910
38.0046	9	AMGNRLVEA	KSHV.172	0.0200
38.0047	9	RLVEACNLL	KSHV.176	0.0180
38.0059	9	TLSIVTFSL	KSHV.198	0.2200
38.0063	9	KLSVLLLEV	KSHV.292	0.1400
38.0064	9	LLLEVNRSV	KSHV.296	0.0270
38.0068	9	FVSSPTLPV	KSHV.78	0.0350
38.0070	9	AMLVLLAEI	KSHV.281	0.0820
38.0075	9	QMARLAWEA	KSHV.1116	0.0990
38.0131	10	VLAIEGIFMA	KSHV.10	0.0730
38.0132	10	YLYHPLLSP	KSHV.27	0.1400
38.0134	10	SLFEAMLANV	KSHV.49	0.9500
38.0135	10	STTGINQLGL	KSHV.62	0.0710
38.0137	10	LAILTFGSFV	KSHV.88	0.0160
38.0139	10	ALLGSIALLA	KSHV.155	0.0360
38.0141	10	ALLATILAAV	KSHV.161	0.1100
38.0142	10	LLATILAAVA	KSHV.162	0.0110
38.0143	10	RLFADELAAL	KSHV.14	0.1800
38.0148	10	YLSKCTLAVL	KSHV.65	0.0300
38.0150	10	LLVYHIYSKI	KSHV.152	0.0130
38.0151	10	SMYLCILSAL	KSHV.208	0.0360

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
38.0153	10	HLHRQMLSFV	KSHV.68	0.0160
38.0163	10	LLCGKTGAFL	KSHV.167	0.0100
38.0164	10	ETLSIVTFSL	KSHV.197	0.0180
39.0063	9	VMCTYSPPL	mp53.119	1.4000
39.0065	9	KLFCQLAKT	mp53.129	0.0160
39.0067	9	ATPPAGSRV	mp53.146	0.0130
39.0133	10	FLQSGTAKSV	mp53.110	0.0180
39.0169	10	CMDRGLTVFV	KSHV.311	0.0120
39.0170	10	VLLNWWRWRL	KSHV.327	0.1500
40.0070	9	GVFTGLTHI	HCV.1565	0.0110
40.0072	9	QMWKCLIRL	HCV.1611	0.0620
40.0074	9	IMTCMSADL	HCV.1650	0.0121
40.0076	9	ALAAAYCLST	HCV.1674	0.2500
40.0080	9	VLSGKPAII	HCV.1692	0.0150
40.0082	9	FISGIQYLA	HCV.1773	0.1000
40.0134	10	YIMTCMSADL	HCV.1649	0.0300
40.0137	10	AIASLMAFTA	HCV.1791	0.0580
40.0138	10	GLAGAAIGSV	HCV.1838	0.0320
41.0058	8	MIGVLVGV	CEA.692	0.0120
41.0061	9	VLPLAYISL	TRP1	0.0110
41.0062	9	SLGCIFFPL	TRP1	0.9700
41.0063	9	PLAYISLFL	TRP1	0.0220
41.0065	9	LMLFYQVWA	TRP1	0.0270
41.0071	9	NISIYNYFV	TRP1	0.2300
41.0072	9	NISVYNYFV	TRP1	0.0600
41.0075	9	FVWTHYYSV	TRP1	1.5000
41.0077	9	FLTWHRYHL	TRP1	0.5500
41.0078	9	LTWHRYHLL	TRP1	0.1600
41.0082	9	MLQEPSFSL	TRP1	0.6900
41.0083	9	SLPYWNFAT	TRP1	0.0110
41.0088	9	RLPEPQDVA	TRP1	0.0180

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
41.0090	9	VTQCLEVRV	TRP1	0.0160
41.0096	9	LLHTFTDAV	TRP1	0.2700
41.0100	9	NMVPFWPPV	TRP1	0.6200
41.0104	9	AVVGALLLV	TRP1	0.0210
41.0105	9	AVVAALLLV	TRP1	0.0390
41.0108	9	LLVAAIFGV	TRP1	1.9000
41.0112	9	SMDEANQPL	TRP1	0.0770
41.0114	9	VLPLAYISV	TRP1	0.1100
41.0115	9	SLGCIFFPV	TRP1	3.2000
41.0116	9	PLAYISLFV	TRP1	0.0310
41.0117	9	LLLFQQARV	TRP1	0.1100
41.0118	9	LMLFYQVWV	TRP1	2.4000
41.0119	9	LLPSSGPGV	TRP1	0.3700
41.0121	9	NLSIYNYFV	TRP1	0.9700
41.0122	9	NLSVYNYFV	TRP1	0.8700
41.0123	9	FLWTHYYSV	TRP1	5.6000
41.0124	9	SLKKTFLGV	TRP1	0.0224
41.0125	9	FLTWHRYHV	TRP1	0.3800
41.0129	9	MLQEPSFSV	TRP1	1.6000
41.0130	9	SLPYWNFAV	TRP1	0.5700
41.0131	9	ALGKNVCDV	TRP1	0.0160
41.0132	9	SLLISPNSV	TRP1	0.1300
41.0133	9	SLFSQWRVV	TRP1	0.0740
41.0134	9	TLGTLCNSV	TRP1	0.0330
41.0136	9	RLPEPQDVV	TRP1	0.1000
41.0137	9	VLQCLEVRV	TRP1	0.0360
41.0138	9	SLNSFRNTV	TRP1	0.0140
41.0139	9	SLDSFRNTV	TRP1	0.0440
41.0141	9	FLNGTGGQV	TRP1	0.0220
41.0142	9	VLLHTFTDV	TRP1	0.0180
41.0145	9	ALVGALLLV	TRP1	0.2600

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	A*0201
41.0146	9	ALVAALLLV	TRP1	0.5800
41.0147	9	LLVALIFGV	TRP1	1.0000
41.0148	9	YLIRARRSV	TRP1	0.0170
41.0149	9	SMDEANQPV	TRP1	0.1600
41.0151	10	SLGCIFFPLL	TRP1	0.1800
41.0157	10	GMCCPDLSPV	TRP1	0.0950
41.0160	10	AACNQKILTV	TRP1	0.0120
41.0162	10	FLTWHRYHLL	TRP1	0.0830
41.0166	10	SLHNLAHLFL	TRP1	0.3900
41.0174	10	LLLVAAIFGV	TRP1	0.3000
41.0177	10	LLVAAIFGVA	TRP1	0.0820
41.0178	10	ALIFGTASYL	TRP1	0.0230
41.0180	10	SMDEANQPLL	TRP1	0.0250
41.0181	10	LLTDQYQCYA	TRP1	0.0320
41.0183	10	SLGCIFFPLV	TRP1	0.3200
41.0186	10	FLMLFYQVWV	TRP1	0.8100
41.0189	10	ALCDQQRVLIV	TRP1	0.0530
41.0190	10	ALCNQKILTV	TRP1	0.0770
41.0191	10	FLTWHRYHLV	TRP1	0.0510
41.0197	10	SLHNLAHLFV	TRP1	0.5000
41.0198	10	NLAHLFLNGV	TRP1	0.4100
41.0199	10	NMVPFWPPVV	TRP1	0.2800
41.0201	10	ILVVAALLLV	TRP1	0.0190
41.0203	10	LLVALIFGTV	TRP1	0.1200
41.0205	10	ALIFGTASYV	TRP1	0.0900
41.0206	10	SMDEANQPLV	TRP1	0.0350
41.0207	10	LLTDQYQCYV	TRP1	0.2100
41.0212	11	LLIQNIQNDT	CEA.107	0.0140
41.0214	11	IIQNDTGfYTL	CEA.112	0.0130
41.0221	11	TLFNVTRNDTA	CEA.201	0.0110
41.0235	11	LTLFSVTRNDV	CEA.378	0.0150

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
41.0243	11	GLYTCQANNSA	CEA.473	0.0290
41.0268	11	ATVGIMIGVLV	CEA.687	0.0160
44.0075	11	GLVPPQHLIRV	mp53.184.V3	0.0370
44.0087	11	GLAPPVHLIRV	mp53.184.V6	0.0330
44.0092	11	GLAPPEHLIRV	mp53.184.E6	0.1600
1227.10	9	ILIGVLVGV	CEA.691.L2	0.2300
1234.26	10	YLIMVKCWMV	Her2/neu.952.L2	0.3800
			V10	
1295.06	9	LLGRDSFEV	mp53.261	0.2000
1319.01	9	FMYSDFHFI	Flu.RRP2.446	0.4400
1319.06	9	NMLSTVLGV	Flu.RRP2.446	0.1700
1319.14	9	SLENFRAYV	Flu.RRP2.446	0.0430
1325.06		KMAELVHFV	Mage3.112	0.1900
1325.07		KLAELVHFV	Mage3.112	0.3500
1334.01		VLIQRNPQV	Her2/neu.153.V9	0.0910
1334.02		VLLGVVFGV	Her2/neu.665.L2	2.1000
			V9	
1334.03		SLISAVVGV	Her2/neu.653.L2	0.7000
			V9	
1334.04		YMIMVKBWMI	Her2/neu.952.B7	0.2700
1334.05		YLIMVKBWMV	Her2/neu.952.L2	0.6900
			B7V10	
1334.06		KLWEELSVV	Mage3.220.L2V	0.4500
			9	
1334.08		AMBRWGLLV	Her2/neu.5.M2B	0.1400
			3V9	
1345.01	9	IIGVLVGV	CEA.691.J2	0.0570
1345.02	9	ATVGIIIGV	CEA.687.J6	0.1595
1345.03	9	SJPPPGTRV	p53.149.J2	0.0545
1345.04	10	LVFGIELJEV	MAGE3.160.J8	0.7650
918.12	8	ILGFVFTL	Flu.M1.59	0.7900

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	A*0201
1095.22	9	KIFGSLAFL	Her2/neu	
1090.01	10	YLQLVFGIEV	MAGE2	
1126.01	9	MMNDQLMFL	PSM	
1126.02	10	ALVLAGGFFL	PSM	
1126.03	9	WLCAGALVL	PSM	
1126.05	9	MVFELANSI	PSM	
1126.06	10	RMMNDQLMFL	PSM	
1126.09	9	LVLAGGFFL	PSM	
1126.10	9	VLAGGFFLL	PSM	
1126.12	9	LLHETDSAV	PSM	
1126.14	9	LMYSLVHNL	PSM	
1126.16	10	QLMFLERAFI	PSM	
1126.17	9	LMFLERAFI	PSM	
1126.20	10	KLGSGNDFEV	PSM	
1129.01	10	LLQERGVAYI	PSM	
1129.04	10	GMPEGDLVYV	PSM	
1129.05	10	FLDELKAENI	PSM	
1129.08	9	ALFDIESKV	PSM	
1129.10	10	GLPSIPVHPI	PSM	

II. Non-HLA-A2 Motifs

The present invention also relates to the determination of allele-specific peptide motifs for human Class I MHC (sometimes referred to as HLA) allele subtypes.

- 5 These motifs are then used to define T cell epitopes from any desired antigen, particularly those associated with human viral diseases, cancers or autoimmune diseases, for which the amino acid sequence of the potential antigen or autoantigen targets is known.

- Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), hepatitis
- 10 B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens and human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, and Her2/neu.

Peptides comprising the epitopes from these antigens are synthesized and then tested for their ability to bind to the appropriate MHC molecules in assays using, for example, purified class I molecules and radioiodinated peptides and/or cells expressing empty class I molecules by, for instance, immunofluorescent staining and flow microfluorimetry, peptide-dependent class I assembly assays, and inhibition of CTL recognition by peptide competition. Those peptides that bind to the class I molecule are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with virally infected target cells or tumor cells as potential therapeutic agents.

The MHC class I antigens are encoded by the HLA-A, B, and C loci. HLA-A and B antigens are expressed at the cell surface at approximately equal densities, whereas the expression of HLA-C is significantly lower (perhaps as much as 10-fold lower). Each of these loci have a number of alleles. The peptide binding motifs of the invention are relatively specific for each allelic subtype.

For peptide-based vaccines, the peptides of the present invention preferably comprise a motif recognized by an MHC I molecule having a wide distribution in the human population. Since the MHC alleles occur at different frequencies within different ethnic groups and races, the choice of target MHC allele may depend upon the target population. Table 4 shows the frequency of various alleles at the HLA-A locus products among different races. For instance, the majority of the Caucasoid population can be covered by peptides which bind to four HLA-A allele subtypes, specifically HLA-A2.1, A1, A3.2, and A24.1. Similarly, the majority of the Asian population is encompassed with the addition of peptides binding to a fifth allele HLA-A11.2.

TABLE 4

<u>A Allele/Subtype</u>	<u>N(69)*</u>	<u>A(54)</u>	<u>C(502)</u>
A1	10.1(7)	1.8(1)	27.4(138)
A2.1	11.5(8)	37.0(20)	39.8(199)
A2.2	10.1(7)	0	3.3(17)

A2.3	1.4(1)	5.5(3)	0.8(4)
A2.4	-	-	-
A2.5	-	-	-
A3.1	1.4(1)	0	0.2(0)
A3.2	5.7(4)	5.5(3)	21.5(108)
A11.1	0	5.5(3)	0
A11.2	5.7(4)	31.4(17)	8.7(44)
A11.3	0	3.7(2)	0
A23	4.3(3)	-	3.9(20)
A24	2.9(2)	27.7(15)	15.3(77)
A24.2	-	-	-
A24.3	-	-	-
A25	1.4(1)	-	6.9(35)
A26.1	4.3(3)	9.2(5)	5.9(30)
A26.2	7.2(5)	-	1.0(5)
A26V	-	3.7(2)	-
A28.1	10.1(7)	-	1.6(8)
A28.2	1.4(1)	-	7.5(38)
A29.1	1.4(1)	-	1.4(7)
A29.2	10.1(7)	1.8(1)	5.3(27)
A30.1	8.6(6)	-	4.9(25)
A30.2	1.4(1)	-	0.2(1)
A30.3	7.2(5)	-	3.9(20)
A31	4.3(3)	7.4(4)	6.9(35)
A32	2.8(2)	-	7.1(36)
Aw33.1	8.6(6)	-	2.5(13)
Aw33.2	2.8(2)	16.6(9)	1.2(6)
Aw34.1	1.4(1)	-	-
Aw34.2	14.5(10)	-	0.8(4)
Aw36	5.9(4)	-	-

Table compiled from B. DuPont, Immunobiology of HLA, Vol. I, Histocompatibility Testing 1987, Springer-Verlag, New York 1989.

* N - negroid; A = Asian; C = Caucasoid. Numbers in parenthesis represent the number of individuals included in the analysis.

5 The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they
10 would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids is represented by a lower case single letter or a lower case three letter symbol. Glycine
15 has no asymmetric carbon atom and is simply referred to as "Gly" or G.

 The procedures used to identify peptides of the present invention generally follow the methods disclosed in Falk et al., Nature 351:290 (1991), which is incorporated herein by reference. Briefly, the methods involve large-scale isolation of MHC class I molecules, typically by immunoprecipitation or affinity chromatography, from the
20 appropriate cell or cell line. Examples of other methods for isolation of the desired MHC molecule equally well known to the artisan include ion exchange chromatography, lectin chromatography, size exclusion, high performance ligand chromatography, and a combination of all of the above techniques.

 A large number of cells with defined MHC molecules, particularly MHC
25 Class I molecules, are known and readily available. For example, human EBV-transformed B cell lines have been shown to be excellent sources for the preparative isolation of class I and class II MHC molecules. Well-characterized cell lines are available from private and commercial sources, such as American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas," 6th edition (1988) Rockville,
30 Maryland, U.S.A.); National Institute of General Medical Sciences 1990/1991 Catalog of Cell Lines (NIGMS) Human Genetic Mutant Cell Repository, Camden, NJ; and ASHI Repository, Bingham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Table 5 lists some B cell lines suitable for use as sources for HLA-A alleles. All of these cell lines can be grown in large batches and are therefore useful for large scale production

of MHC molecules. One of skill will recognize that these are merely exemplary cell lines and that many other cell sources can be employed. Similar EBV B cell lines homozygous for HLA-B and HLA-C could serve as sources for HLA-B and HLA-C alleles, respectively.

5

TABLE 5

HUMAN CELL LINES (HLA-A SOURCES)

HLA-A allele	B cell line
A1	MAT COX (9022) STEINLIN (9087)
A2.1	JY
A3.2	EHM (9080) HO301 (9055)GM3107
A24.1	T3(9107),TISI (9042)
A11	BVR (GM6828A) WT100 (GM8602)WT52 (GM8603)

In the typical case, immunoprecipitation is used to isolate the desired allele. A number of protocols can be used, depending upon the specificity of the antibodies used. For example, allele-specific mAb reagents can be used for the affinity purification of the HLA-A, HLA-B, and HLA-C molecules. Several mAb reagents for the isolation of HLA-A molecules are available (Table 6). Thus, for each of the targeted HLA-A alleles, reagents are available that may be used for the direct isolation of the HLA-A molecules. Affinity columns prepared with these mAbs using standard techniques are successfully used to purify the respective HLA-A allele products.

In addition to allele-specific mAbs, broadly reactive anti-HLA-A, B, C mAbs, such as W6/32 and B9.12.1, and one anti-HLA-B, C mAb, B1.23.2, could be used in alternative affinity purification protocols as described in the example section below.

TABLE 6

ANTIBODY REAGENTS

anti-HLA	Name	
HLA-A1	12/18	
HLA-A3	GAPA3	(ATCC, HB122)
HLA-11,24.1	A11.1M	(ATCC, HB164)
HLA-A,B,C	W6/32	(ATCC, HB95)
monomorphic	B9.12.1	(INSERM-CNRS)
HLA-B,C	B.1.23.2	(INSERM-CNRS)
monomorphic		

5 The peptides bound to the peptide binding groove of the isolated MHC molecules are eluted typically using acid treatment. Peptides can also be dissociated from class I molecules by a variety of standard denaturing means, such as heat, pH, detergents, salts, chaotropic agents, or a combination thereof.

10 Peptide fractions are further separated from the MHC molecules by reversed-phase high performance liquid chromatography (HPLC) and sequenced. Peptides can be separated by a variety of other standard means well known to the artisan, including filtration, ultrafiltration, electrophoresis, size chromatography, precipitation with specific antibodies, ion exchange chromatography, isoelectrofocusing, and the like.

15 Sequencing of the isolated peptides can be performed according to standard techniques such as Edman degradation (Hunkapiller, M.W., et al., Methods Enzymol. 91, 399 [1983]). Other methods suitable for sequencing include mass spectrometry sequencing of individual peptides as previously described (Hunt, et al., Science 225:1261 (1992), which is incorporated herein by reference). Amino acid sequencing of bulk heterogenous peptides (e.g., pooled HPLC fractions) from different
20 class I molecules typically reveals a characteristic sequence motif for each class I allele.

 Definition of motifs specific for different class I alleles allows the identification of potential peptide epitopes from an antigenic protein whose amino acid sequence is known. Typically, identification of potential peptide epitopes is initially

carried out using a computer to scan the amino acid sequence of a desired antigen for the presence of motifs. The epitopic sequences are then synthesized. The capacity to bind MHC Class molecules is measured in a variety of different ways. One means is a Class I molecule binding assay as described in the related applications, noted above. Other

5 alternatives described in the literature include inhibition of antigen presentation (Sette, et al., J. Immunol. 141:3893 (1991), in vitro assembly assays (Townsend, et al., Cell 62:285 (1990), and FACS based assays using mutated cells, such as RMA.S (Melief, et al., Eur. J. Immunol. 21:2963 (1991)).

Next, peptides that test positive in the MHC class I binding assay are

10 assayed for the ability of the peptides to induce specific CTL responses in vitro. For instance, Antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells (Inaba, et al., J. Exp. Med. 166:182 (1987); Boog, Eur. J. Immunol. 18:219 [1988]).

15 Alternatively, mutant mammalian cell lines that are deficient in their ability to load class I molecules with internally processed peptides, such as the mouse cell lines RMA-S (Kärre, et al., Nature, 319:675 (1986); Ljunggren, et al., Eur. J. Immunol. 21:2963-2970 (1991)), and the human somatic T cell hybrid, T-2 (Cerundolo, et al., Nature 345:449-452 (1990)) and which have been transfected with the appropriate human

20 class I genes are conveniently used, when peptide is added to them, to test for the capacity of the peptide to induce in vitro primary CTL responses. Other eukaryotic cell lines which could be used include various insect cell lines such as mosquito larvae (ATCC cell lines CCL 125, 126, 1660, 1591, 6585, 6586), silkworm (ATTC CRL 8851), armyworm (ATCC CRL 1711), moth (ATCC CCL 80) and Drosophila cell lines such as a Schneider

25 cell line (see Schneider J. Embryol. Exp. Morphol. 27:353-365 [1927]).

Peripheral blood lymphocytes are conveniently isolated following simple venipuncture or leukapheresis of normal donors or patients and used as the responder cell sources of CTL precursors. In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100 μ M of peptide in serum-free media for 4 hours under

30 appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the responder cell populations in vitro for 7 to 10 days under optimized culture conditions. Positive CTL activation can be determined by assaying the cultures for the presence of CTLs that kill radiolabeled target cells, both specific peptide-pulsed

targets as well as target cells expressing endogenously processed form of the relevant virus or tumor antigen from which the peptide sequence was derived.

Specificity and MHC restriction of the CTL is determined by testing against different peptide target cells expressing appropriate or inappropriate human MHC class I. The peptides that test positive in the MHC binding assays and give rise to specific CTL responses are referred to herein as immunogenic peptides.

The immunogenic peptides can be prepared synthetically, or by recombinant DNA technology or from natural sources such as whole viruses or tumors. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments or particles.

The polypeptides or peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

Desirably, the peptide will be as small as possible while still maintaining substantially all of the biological activity of the large peptide. When possible, it may be desirable to optimize peptides of the invention to a length of 9 or 10 amino acid residues, commensurate in size with endogenously processed viral peptides or tumor cell peptides that are bound to MHC class I molecules on the cell surface.

Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell. For instance, the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding. By conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. The effect of single amino acid substitutions may also be probed using D-amino acids. Such modifications may be made

using well known peptide synthesis procedures, as described in e.g., Merrifield, Science 232:341-347 (1986), Barany and Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp. 1-284 (1979); and Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984), incorporated by reference herein.

5 The peptides can also be modified by extending or decreasing the compound's amino acid sequence, e.g., by the addition or deletion of amino acids. The peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e.g., those at critical contact sites or conserved
10 residues, may generally not be altered without an adverse effect on biological activity. The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L- α -amino acids, or their D-isomers, but may include non-natural amino acids as well, such as β - γ - δ -amino acids, as well as many derivatives of L- α -amino acids.

Typically, a series of peptides with single amino acid substitutions are
15 employed to determine the effect of electrostatic charge, hydrophobicity, etc. on binding. For instance, a series of positively charged (e.g., Lys or Arg) or negatively charged (e.g., Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards various MHC molecules and T cell receptors. In addition, multiple substitutions using small, relatively neutral moieties such as Ala, Gly, Pro, or
20 similar residues may be employed. The substitutions may be homo-oligomers or hetero-oligomers. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased binding affinity for an MHC molecule or T cell receptor may also be achieved by such substitutions,
25 compared to the affinity of the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.

Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final
30 peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 2 when it is desired to finely modulate the characteristics of the peptide.

TABLE 2

<u>Original Residue</u>	<u>Exemplary Substitution</u>
Ala	Ser
Arg	Lys, His
Asn	Gln
Asp	Glu
Cys	Ser
Glu	Asp
Gly	Pro
His	Lys; Arg
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; His
Met	Leu; Ile
Phe	Tyr; Trp
Ser	Thr
Thr	Ser
Trp	Tyr; Phe
Tyr	Trp; Phe
Val	Ile; Leu
Pro	Gly

- Substantial changes in function (e.g., affinity for MHC molecules or T cell receptors) are made by selecting substitutions that are less conservative than those in Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which (a) hydrophilic residue, e.g. seryl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g.

glutamyl or aspartyl; or (c) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

The peptides may also comprise isosteres of two or more residues in the immunogenic peptide. An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence because the steric conformation of the first sequence fits a binding site specific for the second sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the α -carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, peptides and Proteins, Vol. VII (Weinstein ed., 1983).

Modifications of peptides with various amino acid mimetics or unnatural amino acids are particularly useful in increasing the stability of the peptide in vivo. Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokin. 11:291-302 (1986). Half life of the peptides of the present invention is conveniently determined using a 25% human serum (v/v) assay. The protocol is generally as follows. Pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloroacetic acid or ethanol. The cloudy reaction sample is cooled (4°C) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability-specific chromatography conditions.

The peptides of the present invention or analogs thereof which have CTL stimulating activity may be modified to provide desired attributes other than improved serum half life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Particularly preferred immunogenic peptides/T helper conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically

selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. Alternatively, the CTL peptide may be linked to the T helper peptide without a spacer.

The immunogenic peptide may be linked to the T helper peptide either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated. Exemplary T helper peptides include tetanus toxoid 830-843, influenza 307-319, malaria circumsporozoite 382-398 and 378-389.

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes CTL. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the alpha and epsilon amino groups of a Lys residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment a particularly effective immunogen comprises palmitic acid attached to alpha and epsilon amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P3CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide. See, Deres et al., *Nature* 342:561-564 (1989), incorporated herein by reference. Peptides of the invention can be coupled to P³CSS, for example, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Further, as the induction of neutralizing antibodies can also be primed with P³CSS conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to more effectively elicit both humoral and cell-mediated responses to infection.

In addition, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support, or

larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide. Modification at the C terminus in some cases may alter binding

5 characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH₂-acylation, e.g., by alkanoyl (C₁-C₂₀) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

10 The peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed.,

15 Pierce Chemical Co. (1984), supra.

Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the

20 art, as described generally in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1982), which is incorporated herein by reference. Thus, fusion proteins which comprise one or more peptide sequences of the invention can be used to present the appropriate T cell epitope.

As the coding sequence for peptides of the length contemplated herein can

25 be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981), modification can be made simply by substituting the appropriate base(s) for those encoding the native peptide sequence. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform

30 suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for

expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast or mammalian cell hosts may also be used, employing suitable vectors and control sequences.

The peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent viral infection and cancer. Examples of diseases which can be treated using the immunogenic peptides of the invention include prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV and condyloma acuminatum.

For pharmaceutical compositions, the immunogenic peptides of the invention are administered to an individual already suffering from cancer or infected with the virus of interest. Those in the incubation phase or the acute phase of infection can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate. In therapeutic applications, compositions are administered to a patient in an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and to cure or at least partially arrest symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0 μg to about 5000 μg of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0 μg to about 1000 μg of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

For therapeutic use, administration should begin at the first sign of viral infection or the detection or surgical removal of tumors or shortly after diagnosis in the case of acute infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses

5 followed by boosting doses may be required.

Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals. For those individuals susceptible (or predisposed) to developing chronic infection the compositions are particularly useful in methods for preventing the evolution from acute to chronic
10 infection. Where the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.

The peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eliminate virus-infected cells in carriers.
15 It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate a cytotoxic T cell response. Thus, for treatment of chronic infection, a representative dose is in the range of about 1.0 μg to about 5000 μg , preferably about 5 μg to 1000 μg for a 70 kg patient per dose. Immunizing doses followed by boosting doses at established intervals, e.g., from one to
20 four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.

The pharmaceutical compositions for therapeutic treatment are intended
25 for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety
30 of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined

with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of CTL stimulatory peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or targeted selectively to infected cells, as well as increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, incorporated herein by reference.

For targeting to the immune cells, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies

according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

In another aspect the present invention is directed to vaccines which contain as an active ingredient an immunogenically effective amount of an immunogenic peptide as described herein. The peptide(s) may be introduced into a host, including humans, linked to its own carrier or as a homopolymer or heteropolymer of active peptide units. Such a polymer has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the virus or tumor cells. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant,

aluminum phosphate, aluminum hydroxide, or alum are materials well known in the art. And, as mentioned above, CTL responses can be primed by conjugating peptides of the invention to lipids, such as P₃CSS. Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen, and the host becomes at least partially immune to later infection, or resistant to developing chronic infection.

Vaccine compositions containing the peptides of the invention are administered to a patient susceptible to or otherwise at risk of viral infection or cancer to elicit an immune response against the antigen and thus enhance the patient's own immune response capabilities. Such an amount is defined to be an "immunogenically effective dose." In this use, the precise amounts again depend on the patient's state of health and weight, the mode of administration, the nature of the formulation, etc., but generally range from about 1.0 µg to about 5000 µg per 70 kilogram patient, more commonly from about 10 µg to about 500 µg mg per 70 kg of body weight.

In some instances it may be desirable to combine the peptide vaccines of the invention with vaccines which induce neutralizing antibody responses to the virus of interest, particularly to viral envelope antigens.

For therapeutic or immunization purposes, nucleic acids encoding one or more of the peptides of the invention can also be administered to the patient. A number of methods are conveniently used to deliver the nucleic acids to the patient. For instance, the nucleic acid can be delivered directly, as "naked DNA". This approach is described, for instance, in Wolff et. al., *Science* 247:1465-1468 (1990) as well as U.S. Patent Nos. 5,580,859 and 5,589,466. The nucleic acids can also be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Particles comprised solely of DNA can be administered. Alternatively, DNA can be adhered to particles, such as gold particles. The nucleic acids can also be delivered complexed to cationic compounds, such as cationic lipids. Lipid-mediated gene delivery methods are described, for instance, in WO 96/18372; WO 93/24640; Mannino and Gould-Fogerite (1988) *BioTechniques* 6(7):682-691; Rose U.S. Pat No. 5,279,833; WO 91/06309; and Felgner et al. (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414. The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode

the peptides of the invention. Upon introduction into an acutely or chronically infected host or into a noninfected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits a host CTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No.

5 4,722,848, incorporated herein by reference. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al. (Nature 351:456-460 (1991)) which is incorporated herein by reference. A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g., Salmonella typhi vectors and the like, will be apparent to those skilled in the art from the description
10 herein.

A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding multiple epitopes of the invention. To create a DNA sequence encoding the selected CTL epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes are reverse translated. A human
15 codon usage table is used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences are directly adjoined, creating a continuous polypeptide sequence. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequence that could be reverse translated and included in the minigene sequence include: helper T lymphocyte
20 epitopes, a leader (signal) sequence, and an endoplasmic reticulum retention signal. In addition, MHC presentation of CTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL epitopes.

The minigene sequence is converted to DNA by assembling
25 oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides are joined using T4 DNA ligase. This synthetic minigene, encoding the CTL epitope polypeptide, can then be cloned into a desired expression vector.

30 Standard regulatory sequences well known to those of skill in the art are included in the vector to ensure expression in the target cells. Several vector elements are required: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an E. coli origin of

replication; and an *E. coli* selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. *See*, U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

5 Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences can also be considered for increasing minigene expression. It has
10 recently been proposed that immunostimulatory sequences (ISSs or CpGs) play a role in the immunogenicity of DNA vaccines. These sequences could be included in the vector, outside the minigene coding sequence, if found to enhance immunogenicity.

In some embodiments, a bioisotonic expression vector, to allow production of the minigene-encoded epitopes and a second protein included to enhance or decrease
15 immunogenicity can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e.g. LeIF) or costimulatory molecules. Helper (HTL) epitopes could be joined to intracellular targeting signals and expressed separately from the CTL epitopes. This would allow direction of the HTL epitopes to a
20 cell compartment different than the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the MHC class II pathway, thereby improving CTL induction. In contrast to CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF- β) may be beneficial in certain diseases.

25 Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis.
30 Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

Therapeutic quantities of plasmid DNA are produced by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate

fermentation medium (such as Terrific Broth), and grown to saturation in shaker flasks or a bioreactor according to well known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by Quiagen. If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). A variety of methods have been described, and new techniques may become available. As noted above, nucleic acids are conveniently formulated with cationic lipids. In addition, glycolipids, fusogenic liposomes, peptides and compounds referred to collectively as protective, interactive, non-condensing (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay for expression and MHC class I presentation of minigene-encoded CTL epitopes. The plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct *in vitro* transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 labeled and used as target cells for epitope-specific CTL lines. Cytolysis, detected by ⁵¹Cr release, indicates production of MHC presentation of minigene-encoded CTL epitopes.

In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human MHC molecules are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g. IM for DNA in PBS, IP for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for 1 week in the presence of peptides encoding each epitope being tested. These effector cells (CTLs) are assayed for cytolysis of peptide-loaded, chromium-51 labeled target cells using standard techniques. Lysis of target cells sensitized by MHC loading of peptides corresponding to minigene-encoded epitopes demonstrates DNA vaccine function for *in vivo* induction of CTLs.

Antigenic peptides may be used to elicit CTL *ex vivo*, as well. The resulting CTL, can be used to treat chronic infections (viral or bacterial) or tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a peptide vaccine approach of therapy. *Ex vivo* CTL responses to a particular pathogen (infectious agent or tumor antigen) are induced by incubating in tissue culture the patient's CTL precursor cells (CTLp) together with a source of antigen-presenting cells (APC) and the appropriate immunogenic peptide. After an appropriate incubation time (typically 1-4 weeks), in which the CTLp are activated and mature and expand into effector CTL, the cells are infused back into the patient, where they will destroy their specific target cell (an infected cell or a tumor cell). In order to optimize the *in vitro* conditions for the generation of specific cytotoxic T cells, the culture of stimulator cells is maintained in an appropriate serum-free medium.

Prior to incubation of the stimulator cells with the cells to be activated, e.g., precursor CD8+ cells, an amount of antigenic peptide is added to the stimulator cell culture, of sufficient quantity to become loaded onto the human Class I molecules to be expressed on the surface of the stimulator cells. In the present invention, a sufficient amount of peptide is an amount that will allow about 200, and preferably 200 or more, human Class I MHC molecules loaded with peptide to be expressed on the surface of each stimulator cell. Preferably, the stimulator cells are incubated with >20µg/ml peptide.

Resting or precursor CD8+ cells are then incubated in culture with the appropriate stimulator cells for a time period sufficient to activate the CD8+ cells. Preferably, the CD8+ cells are activated in an antigen-specific manner. The ratio of resting or precursor CD8+ (effector) cells to stimulator cells may vary from individual to individual and may further depend upon variables such as the amenability of an individual's lymphocytes to culturing conditions and the nature and severity of the disease condition or other condition for which the within-described treatment modality is used. Preferably, however, the lymphocyte:stimulator cell ratio is in the range of about 30:1 to 300:1. The effector/stimulator culture may be maintained for as long a time as is necessary to stimulate a therapeutically useable or effective number of CD8+ cells.

The induction of CTL *in vitro* requires the specific recognition of peptides that are bound to allele specific MHC class I molecules on APC. The number of specific MHC/peptide complexes per APC is crucial for the stimulation of CTL, particularly in primary immune responses. While small amounts of peptide/MHC complexes per cell

are sufficient to render a cell susceptible to lysis by CTL, or to stimulate a secondary CTL response, the successful activation of a CTL precursor (pCTL) during primary response requires a significantly higher number of MHC/peptide complexes. Peptide loading of empty major histocompatibility complex molecules on cells allows the induction of primary cytotoxic T lymphocyte responses. Peptide loading of empty major histocompatibility complex molecules on cells enables the induction of primary cytotoxic T lymphocyte responses.

Since mutant cell lines do not exist for every human MHC allele, it is advantageous to use a technique to remove endogenous MHC-associated peptides from the surface of APC, followed by loading the resulting empty MHC molecules with the immunogenic peptides of interest. The use of non-transformed (non-tumorigenic), non-infected cells, and preferably, autologous cells of patients as APC is desirable for the design of CTL induction protocols directed towards development of *ex vivo* CTL therapies. This application discloses methods for stripping the endogenous MHC-associated peptides from the surface of APC followed by the loading of desired peptides.

A stable MHC class I molecule is a trimeric complex formed of the following elements: 1) a peptide usually of 8 - 10 residues, 2) a transmembrane heavy polymorphic protein chain which bears the peptide-binding site in its $\alpha 1$ and $\alpha 2$ domains, and 3) a non-covalently associated non-polymorphic light chain, β_2 microglobulin. Removing the bound peptides and/or dissociating the β_2 microglobulin from the complex renders the MHC class I molecules nonfunctional and unstable, resulting in rapid degradation. All MHC class I molecules isolated from PBMCs have endogenous peptides bound to them. Therefore, the first step is to remove all endogenous peptides bound to MHC class I molecules on the APC without causing their degradation before exogenous peptides can be added to them.

Two possible ways to free up MHC class I molecules of bound peptides include lowering the culture temperature from 37°C to 26°C overnight to destabilize β_2 microglobulin and stripping the endogenous peptides from the cell using a mild acid treatment. The methods release previously bound peptides into the extracellular environment allowing new exogenous peptides to bind to the empty class I molecules. The cold-temperature incubation method enables exogenous peptides to bind efficiently to the MHC complex, but requires an overnight incubation at 26°C which may slow the cell's metabolic rate. It is also likely that cells not actively synthesizing MHC molecules

(e.g., resting PBMC) would not produce high amounts of empty surface MHC molecules by the cold temperature procedure.

Harsh acid stripping involves extraction of the peptides with trifluoroacetic acid, pH 2, or acid denaturation of the immunoaffinity purified class I-peptide complexes.

5 These methods are not feasible for CTL induction, since it is important to remove the endogenous peptides while preserving APC viability and an optimal metabolic state which is critical for antigen presentation. Mild acid solutions of pH 3 such as glycine or citrate-phosphate buffers have been used to identify endogenous peptides and to identify tumor associated T cell epitopes. The treatment is especially effective, in that only the
10 MHC class I molecules are destabilized (and associated peptides released), while other surface antigens remain intact, including MHC class II molecules. Most importantly, treatment of cells with the mild acid solutions do not affect the cell's viability or metabolic state. The mild acid treatment is rapid since the stripping of the endogenous peptides occurs in two minutes at 4°C and the APC is ready to perform its function after
15 the appropriate peptides are loaded. The technique is utilized herein to make peptide-specific APCs for the generation of primary antigen-specific CTL. The resulting APC are efficient in inducing peptide-specific CD8+ CTL.

Activated CD8+ cells may be effectively separated from the stimulator cells using one of a variety of known methods. For example, monoclonal antibodies
20 specific for the stimulator cells, for the peptides loaded onto the stimulator cells, or for the CD8+ cells (or a segment thereof) may be utilized to bind their appropriate complementary ligand. Antibody-tagged molecules may then be extracted from the stimulator-effector cell admixture via appropriate means, e.g., via well-known immunoprecipitation or immunoassay methods.

25 Effective, cytotoxic amounts of the activated CD8+ cells can vary between *in vitro* and *in vivo* uses, as well as with the amount and type of cells that are the ultimate target of these killer cells. The amount will also vary depending on the condition of the patient and should be determined via consideration of all appropriate factors by the practitioner. Preferably, however, about 1×10^6 to about 1×10^{12} , more preferably about
30 1×10^8 to about 1×10^{11} , and even more preferably, about 1×10^9 to about 1×10^{10} activated CD8+ cells are utilized for adult humans, compared to about 5×10^6 - 5×10^7 cells used in mice.

Preferably, as discussed above, the activated CD8+ cells are harvested from the cell culture prior to administration of the CD8+ cells to the individual being treated. It is important to note, however, that unlike other present and proposed treatment modalities, the present method uses a cell culture system that is not tumorigenic.

- 5 Therefore, if complete separation of stimulator cells and activated CD8+ cells is not achieved, there is no inherent danger known to be associated with the administration of a small number of stimulator cells, whereas administration of mammalian tumor-promoting cells may be extremely hazardous.

10 Methods of re-introducing cellular components are known in the art and include procedures such as those exemplified in U.S. Patent No. 4,844,893 to Honsik, et al. and U.S. Patent No. 4,690,915 to Rosenberg. For example, administration of activated CD8+ cells via intravenous infusion is appropriate.

The immunogenic peptides of this invention may also be used to make monoclonal antibodies. Such antibodies may be useful as potential diagnostic or
15 therapeutic agents.

The peptides may also find use as diagnostic reagents. For example, a peptide of the invention may be used to determine the susceptibility of a particular individual to a treatment regimen which employs the peptide or related peptides, and thus may be helpful in modifying an existing treatment protocol or in determining a prognosis
20 for an affected individual. In addition, the peptides may also be used to predict which individuals will be at substantial risk for developing chronic infection.

To identify peptides of the invention, class I antigen isolation, and isolation and sequencing of naturally processed peptides was carried out as described in the related applications. These peptides were then used to define specific binding motifs
25 for each of the following alleles A3.2, A1, A11, and A24.1. These motifs are described on page 3, above. The motifs described in Tables 8-11, below, are defined from pool sequencing data of naturally processed peptides as described in the related applications.

TABLE 8

Summary

HLA-A3.2 Allele-Specific Motif

Position	Conserved Residues
1	-

2	V,L,M
3	Y,D
4	-
5	-
6	-
7	I
8	Q,N
9	K
10	K

TABLE 9

Summary

HLA-A1 Allele-Specific Motif

Position	Conserved Residues
1	-
2	S,T
3	D,E
4	P
5	-
6	-
7	L
8	-
9	Y
10	K

TABLE 10

Summary

HLA-A11 Allele-Specific Motif

Position	Conserved Residues
1	-
2	T,V

3	M,F
4	-
5	-
6	-
7	-
8	Q
9	K
10	K

TABLE 11

Summary

HLA-A24.1 Allele-Specific Motif

Position	Conserved Residues
1	-
2	Y
3	I,M
4	D,E,G,K,P
5	L,M,N
6	V
7	N,V
8	A,E,K,Q,S
9	F,L
10	F,A

Example 2

5

Identification of immunogenic peptides

Using the motifs identified above for various MHC class I allele amino acid sequences from various pathogens and tumor-related proteins were analyzed for the presence of these motifs. Screening was carried out described in the related applications. Table 12 provides the results of searches of the antigens.

10

Table 12

Peptide	AA	Sequence	Source	A*0301	A*1101
28.0719	10	ILEQWVAGRK	HDV.nuc.16	0.0170	0.0012
28.0727	10	LSAGGKNLSK	HDV.nuc.115	0.0097	0.0150
1259.02	11	STDTVDTVLEK	Flu.HA.29	0.0001	0.0670
1259.04	9	GIAPLQLGK	Flu.HA.63	0.6100	0.2000
1259.06	10	VTAACSHAGK	Flu.HA.149	0.0380	0.0490
1259.08	9	GIHHPNSK	Flu.HA.195	0.1300	0.0140
1259.10	10	RMNYYWTLLK	Flu.HA.243	2.5000	2.3000
1259.12	11	ITNKVNSVIEK	Flu.HA.392	0.0200	0.0670
1259.13	11	KMNIQFTAVGK	Flu.HA.402	0.0280	0.0092
1259.14	9	NIQFTAVGK	Flu.HA.404	0.0017	0.0330
1259.16	11	AVGKEFNKLEK	Flu.HA.409	0.0210	0.0460
1259.19	11	KVKSQLKNNAK	Flu.HA.465	0.0470	0.0031
1259.20	11	SVRNGTYDYPK	Flu.HA.495	0.0410	0.1400
1259.21	9	SIIPSGPLK	Flu.VMT1.13	0.7800	8.8000
1259.25	10	RMVLASTTAK	Flu.VMT1.178	0.5500	0.0350
1259.26	9	MVLASTTAK	Flu.VMT1.179	1.7000	1.4000
1259.28	10	RMGVQMQRFK	Flu.VMT1.243	0.1000	0.0059
1259.33	10	ATEIRASVGK	Flu.VNUC.22	0.1400	0.3000
1259.37	11	TMVMELVRMIK	Flu.VNUC.188	0.0890	0.0310
1259.43	10	RVLSFIKGTK	Flu.VNUC.342	0.8000	0.0830
F119.01	9	MSLQRQFLR	ORF3P	0.2000	0.7200
F119.02	9	LLGPGRPYR	TRP.197	0.0190	0.0091
F119.03	9	LLGPGRPYK	TRP.197K9	2.2000	0.6800
34.0019	8	RVYPELPK	CEA.139	0.0130	0.0440
34.0020	8	TVSAELPK	CEA.495	0.0037	0.0320
34.0021	8	TVYAEPPK	CEA.317	0.0160	0.0220
34.0029	8	TINYTLWR	MAGE2.74	0.0140	0.0550
34.0030	8	LVHFLLLK	MAGE2.116	0.0290	0.1500
34.0031	8	SVFAHPRK	MAGE2.237	0.1410	0.0810
34.0043	8	KVLHHMVK	MAGE3.285	0.0580	0.0190
34.0050	8	RVCACPGR	p53.273	0.3500	0.0490

34.0051	8	KMFCQLAK	p53.132	0.3800	0.3600
34.0062	8	RAHSSHLK	p53.363	0.5500	0.0071
34.0148	9	FVSNLATGR	CEA.656	0.0019	0.0490
34.0152	9	RLQLSNGNK	CEA.546	0.0250	0.0110
34.0153	9	RINGIPQQK	CEA.628	0.0400	0.0780
34.0154	9	KIRKYTMRK	HER2/neu.681	0.0620	0.0055
34.0155	9	LVHFLLLKK	MAGE2.116	0.5220	1.4000
34.0156	9	SMLEVFEGK	MAGE2.226	0.0950	1.6000
34.0157	9	SSFSTTINK	MAGE2.69	0.1600	2.0000
34.0158	9	TSYVKVLHK	MAGE2.281	0.5300	0.1500
34.0159	9	VIFSKASEK	MAGE2.149	0.4900	0.0530
34.0160	9	GSVVGNWQK	MAGE3.130	0.0040	0.2060
34.0161	9	SSLPTTMNK	MAGE3.69	0.6180	0.7100
34.0162	9	SVLEVFEGK	MAGE3.226	0.1330	0.9000
34.0171	9	SSBMGGMNK	p53.240	0.5440	1.1000
34.0172	9	SSCMGGMNK	p53.240	0.0090	0.0490
34.0211	10	RTLTLFNVTK	CEA.554	0.2200	1.3000
34.0212	10	TISPLNTSYK	CEA.241	0.1800	0.0330
34.0214	10	STTINYTLWK	MAGE2.72	0.0870	0.6500
34.0215	10	ASSLPTTMNK	MAGE3.68	0.0420	0.0270
34.0225	10	KTYQGSYGFK	p53.101	0.4900	0.4200
34.0226	10	VVRRBPHHEK	p53.172	0.1800	0.2100
34.0228	10	GLAPPQHLIK	p53.187	0.0570	0.0160
34.0229	10	NSSCMGGMNK	p53.239	0.0071	0.0290
34.0230	10	SSBMGGMNRK	p53.240	0.0420	0.1600
34.0232	10	RVCACPGRDK	p53.273	0.0190	0.0250
34.0295	11	KTITVSAELPK	CEA.492	0.3600	0.1600
34.0296	11	TTITVYAEPPK	CEA.314	0.0200	0.0280
34.0298	11	PTISPSYTYR	CEA.418	(0.0002)	0.1300
34.0301	11	GLLGDNQVMPK	MAGE2.188	0.0780	0.0047
34.0306	11	MVELVHFLLLK	MAGE2.113	0.0200	0.0120
34.0308	11	FSTTINYTLWR	MAGE2.71	0.0110	0.0170

34.0311	11	GLLGDNQIMPK	MAGE3.188	0.1300	0.0570
34.0317	11	RLGFLHSGTAK	p53.110	0.0430	0.0001
34.0318	11	ALNKMFCQLAK	p53.129	0.4400	0.0420
34.0323	11	RVCACPGRR	p53.273	0.0290	0.0290
34.0324	11	LSQETFSDLWK	p53.14	(0.0009)	0.0470
34.0328	11	RAHSSHLKSKK	p53.363	0.0270	0.0038
34.0329	11	VTCTYSPALNK	p53.122	0.0700	0.1200
34.0330	11	GTRVRAMAIYK	p53.154	1.1000	0.3300
34.0332	11	STSRHKKLMFK	p53.376	0.3100	0.1300
40.0107	9	LAARNVLVK	Her2/neu.846	0.0580	0.0285
40.0109	9	MALESILRR	Her2/neu.889	0.0034	0.0237
40.0145	10	ISWLGLRSLR	Her2/neu.450	0.0410	0.0027
40.0147	10	GSGAFGTVYK	Her2/neu.727	0.0660	0.1300
40.0153	10	ASPLDSTFYR	Her2/neu.997	0.0003	0.0670

Example 3

Identification of immunogenic peptides

5 Using the B7-like supermotifs identified in the related applications described above, sequences from various pathogens and tumor-related proteins were analyzed for the presence of these motifs. Screening was carried out described in the related applications. Table 13 provides the results of searches of the antigens.

10 Table 13

Peptide	Sequence	Source
40.0013	SPGLSAGI	CEA.680I8
15 40.0022	KPYDGIPA	Her2/neu.921
40.0023	KPYDGIPI	Her2/neu.921I8
40.0050	APRMPEAA	p53.63
40.0051	APRMPEAI	p53.63I8
40.0055	APAAPTPI	p53.76I8

	40.0057	APTPAAPI	p53.79I8
	40.0059	TPAAPAPI	p53.81I8
	40.0061	APAPAPSI	p53.84I8
	40.0062	SPALNKMF	p53.127
5	40.0063	SPALNKMI	p53.127I8
	40.0117	SPSAPPRI	CEA.3I9
	40.0119	PPHRWCIP	CEA.7I9
	40.0120	GPAYSGREI	CEA.92
	40.0156	MPNQAQMRILI	Her2/neu.706I10
10	40.0157	MPYGCLLDHVI	Her2/neu.801I10
	40.0161	APPHRWCIPW	CEA.6
	40.0162	APPHRWCIP	CEA.6I10
	40.0163	IPWQRLLTA	CEA.13
	40.0164	IPWQRLLTI	CEA.13I10
15	40.0166	LPQHILFGYSI	CEA.58I10
	40.0201	RPRFRELVSF	Her2/neu.966
	40.0202	RPRFRELVSEI	Her2/neu.966I11
	40.0205	PPSPREGPLPA	Her2/neu.1149
	40.0206	PPSPREGPLPI	Her2/neu.1149I11
20	40.0207	GPLPAARPAGA	Her2/neu.1155
	40.0208	GPLPAARPAGI	Her2/neu.1155I11
	40.0231	APAPAAPTPAA	p53.74
	40.0232	APAPAAPTPAI	p53.74I11
	40.0233	APAAPTPAAPA	p53.76
25	40.0234	APAAPTPAAPI	p53.76I11
	45.0003	IPWQRLLI	CEA.13.I8
	45.0004	LPQHILFGI	CEA.58.I8
	45.0007	RPGVNLSI	CEA.428.I8
	45.0010	IPQQHTQI	CEA.632.I8
30	45.0011	TPNNNGTI	CEA.646.I8
	45.0016	CPLHNQEI	Her2/neu.315.I8
	45.0017	KPCARVCI	Her2/neu.336.I8
	45.0019	WPDSLPI	Her2/neu.415.I8

	45.0023	SPYVSRLI	Her2/neu.779.I8
	45.0024	VPIKWMAI	Her2/neu.884.I8
	45.0026	RPRFRELI	Her2/neu.966.I8
	45.0028	APGAGGMI	Her2/neu.1036.I8
5	45.0031	SPGKNGVI	Her2/neu.1174.I8
	45.0037	SPQGASSI	MAGE3.64.I8
	45.0038	YPLWSQSI	MAGE3.77.I8
	45.0044	SPLPSQAI	p53.33.I8
	45.0046	MPEAAPPI	p53.66.I8
10	45.0047	APAPSWPI	p53.86.I8
	45.0051	KPVEDKDAI	CEA.155.I9
	45.0054	IPQQHTQVI	CEA.632.I9
	45.0060	APPVAPAPI	p53.70.I9
	45.0062	APAAPTPAI	p53.76.I9
15	45.0064	PPGTRVRAI	p53.152.I9
	45.0065	APPQHLIRI	p53.189.I9
	45.0071	IPQQHTQVLI	CEA.632.I10
	45.0072	SPGLSAGATI	CEA.680.I10
	45.0073	SPMCKGSRCI	Her2/neu.196.I10
20	45.0074	MPNPEGRTYI	Her2/neu.282.I10
	45.0076	CPLHNQEVTI	Her2/neu.315.I10
	45.0079	KPDLSYMPII	Her2/neu.605.I10
	45.0080	TPSGAMPNQI	Her2/neu.701.I10
	45.0084	GPASPLDSTI	Her2/neu.995.I10
25	45.0091	APPVAPAPAI	p53.70.I10
	45.0092	APAPAAPTPI	p53.74.I10
	45.0093	APTPAAPAPI	p53.79.I10
	45.0094	APSWPLSSSI	p53.88.I10
	45.0103	APTISPLNTSI	CEA.239.I11
30	45.0108	SPSYTTYRPGI	CEA.421.I11
	45.0117	CPSGVKPDLSI	Her2/neu.600.I11
	45.0118	SPLTSIISAVI	Her2/neu.649.I11
	45.0119	IPDGENVKIPI	Her2/neu.740.I11

	45.0124	SPLDSTFYRSI	Her2/neu.998.I11
	45.0128	LPAARPAGATI	Her2/neu.1157.I11
	45.0134	HPRKLLMQDLI	MAGE2.241.I11
	45.0135	GPRALIETSYI	MAGE2.274.I11
5	45.0139	GPRALVETSYI	MAGE3.274.I11
	45.0140	APRMPEAAPPI	p53.63.I11
	45.0141	VPSQKTYQGS I	p53.97.I11
	1145.10	FPHCLAFAY	HBV POL 541 analog
	1145.09	FPVCLAFSY	HBV POL 541 analog
10	26.0570	YPALMPLYACI	HBV.pol.645

The above description is provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

- 1 1. A composition comprising an immunogenic peptide having an
- 2 HLA-A2.1 binding motif, which immunogenic peptide is selected from a group
- 3 consisting of:
- 4 AILTFGSFV,
- 5 HLRDFALAV,
- 6 ALLGSIALL,
- 7 ALLATILAA,
- 8 LLATILAAV,
- 9 RLFADLAA,
- 10 YLSKCTLAV,
- 11 LVYHIYSKI,
- 12 SMYLCILSA,
- 13 YLCILSALV,
- 14 VMFSYLQSL,
- 15 RLHVVAYSA,
- 16 GLQTLGAFV,
- 17 FVEEQMTWA,
- 18 QMTWAQTVV,
- 19 IILDTAIFV,
- 20 AIFVCNAFV,
- 21 AMGNRLVEA,
- 22 RLVEACNLL
- 23 TLSIVTFSL,
- 24 KLSVLLLEV,
- 25 LLEVNRSV,
- 26 FVSSPTLPV,
- 27 AMLVLLAEI,
- 28 QMARLAWEA,
- 29 VLAIEGIFMA,
- 30 YLYHPLLSPV,
- 31 SLFEAMLANV,

32 STTGINQLGL,
33 LAILTFGSFV,
34 ALLGSIALLA,
35 ALLATILAAV,
36 LLATILAAVA,
37 RLFADELAAL,
38 YLSKCTLAVL,
39 LLVYHIYSKI,
40 SMYLCILSAL,
41 HLHRQMLSFV,
42 LLCGKTGAFL,
43 ETLSIVTFSL,
44 VMCTYSPPL,
45 KLFCQLAKT,
46 ATPPAGSRV,
47 FLQSGTAKSV,
48 CMDRGLTVFV,
49 VLLNWWRWRL,
50 GVFTGLTHI,
51 QMWKCLIRL,
52 IMTCMSADL,
53 ALAAYCLST,
54 VLSGKPAII,
55 FISGIQYLA,
56 YIMTCMSADL,
57 AIASLMAFTA,
58 GLAGAAIGSV,
59 MIGVLVGV,
60 VLPLAYISL,
61 SLGCIFFPL,
62 PLAYISLFL,
63 LMLFYQVWA,
64 NISIYNYFV,

65 NISVYNYFV,
66 FVWTHYYSV,
67 FLTWHRYHL,
68 LTWHRYHLL,
69 MLQEPSFSL,
70 SLPYWNFAT,
71 RLPEPQDVA,
72 VTQCLEVRV,
73 LLHTFTDAV,
74 NMVPFWPPV,
75 AVVGALLLV,
76 AVVAALLLV,
77 LLVAAIFGV,
78 SMDEANQPL,
79 VLPLAYISV,
80 SLGCIFFPV,
81 PLAYISLFV,
82 LLLFQQARV,
83 LMLFYQVWV,
84 LLPSSGPGV,
85 NLSIYNYFV,
86 NLSVYNYFV,
87 FLWTHYYSV,
88 SLKKTFLGV,
89 FLTWHRYHV,
90 MLQEPSFSV,
91 SLPYWNFAV,
92 ALGKNVCDV,
93 SLLISPNSV,
94 SLFSQWRVV,
95 TLGTLCNSV,
96 RLPEPQDVV,
97 VLQCLEVRV,

98 SLNSFRNTV,
99 SLDSFRNTV
100 FLNGTGGQV
101 VLLHTFTDV
102 ALVGALLV
103 ALVAALLV,
104 LLVALIFGV,
105 YLIRARRSV,
106 SMDEANQPV,
107 SLGCIFFPLL,
108 GMCCPDLSPV,
109 AACNQKILTV
110 FLTWHRYHLL,
111 SLHNLAHLFL
112 LLLVAAIFGV
113 LLVAAIFGVA,
114 ALIFGTASYL,
115 SMDEANQPLL,
116 LLTDQYQCYA,
117 SLGCIFFPLV,
118 FLMLFYQVWV,
119 ALCDQRVLIV,
120 ALCNQKILTV,
121 FLTWHRYHLV,
122 SLHNLAHLFV,
123 NLAHLFLNGV,
124 NMVPFWPPVV,
125 ILVVAALLV,
126 LLVALIFGTV,
127 ALIFGTASYV,
128 SMDEANQPLV,
129 LLTDQYQCYV,
130 LLIQNIIQNDT,

131 IIQNDTGFYTL,
132 TLFNVTRNDTA
133 LTLLSVTRNDV
134 GLYTCQANNSA,
135 ATVGIMIGVLV,
136 GLVPPQHLIRV,
137 GLAPPVHLIRV,
138 GLAPPEHLIRV,
139 ILIGVLVGV,
140 YLIMVKCWMV,
141 LLGRDSFEV,
142 FMYSDFHFI,
143 NMLSTVLGV
144 SLENFRAYV,
145 KMAELVHFV,
146 KLAELVHFV
147 VLIQRNPQV,
148 VLLGVVFGV,
149 SLISAVVGV,
150 YMIMVKBWMI,
151 YLIMVKBWMV,
152 KLWEELSVV,
153 AMBRWGLLV,
154 IJIGVLVGV,
155 ATVGIIJGV,
156 SJPPPGTRV,
157 LVFGIELJEV,
158 ILGFVFTL,
159 KIFGSLAFL,
160 YLQLVFGIEV,
161 MMNDQLMFL,
162 ALVLAGGFFL,
163 WLCAGALVL,

164 MVFELANSI,
 165 RMMNDQLMFL,
 166 LVLAGGFFL,
 167 VLAGGFFLL,
 168 LLHETDSAV,
 169 LMYSLVHNL,
 170 QLMFLERAFL,
 171 LMFLERAFL,
 172 KLGSGNDFEV,
 173 LLQERGVAYI,
 174 GMPEGDLVYV,
 175 FLDELKAENI,
 176 ALFDIESKV,
 177 and GLPSIPVHPI.
 178
 179

1 2. A method of inducing a cytotoxic T cell response against a
 2 preselected antigen in a patient expressing an HLA-A2.1 MHC product, the method
 3 comprising contacting cytotoxic T cells from the patient with a composition comprising
 4 an immunogenic peptide selected from the group consisting of:

5 AILTFGSFV,
 6 HLRDFALAV,
 7 ALLGSIALL,
 8 ALLATILAA,
 9 LLATILAAV,
 10 RLFADELAA,
 11 YLSKCTLAV,
 12 LVYHIYSKI,
 13 SMYLCILSA,
 14 YLCILSALV,
 15 VMFSYLQSL,
 16 RLHVVYAYSA,

17 GLQTLGAFV,
18 FVEEQMTWA,
19 QMTWAQTVV,
20 IILDTAIFV,
21 AIFVCNAFV,
22 AMGNRLVEA,
23 RLVEACNLL
24 TLSIVTFSL,
25 KLSVLLLEV,
26 LLEVNRSV,
27 FVSSPTLPV,
28 AMLVLLAEI,
29 QMARLAWEA,
30 VLAIEGIFMA,
31 YLYHPLLSPI,
32 SLFEAMLANV,
33 STTGINQLGL,
34 LAILTFGSFV,
35 ALLGSIALLA,
36 ALLATILAAV,
37 LLATILAAVA,
38 RLFADELAAL,
39 YLSKCTLAVL,
40 LLVYHIYSKI,
41 SMYLCILSAL,
42 HLHRQMLSFV,
43 LLCGKTGAFL,
44 ETLSIVTFSL,
45 VMCTYSPPL,
46 KLFCQLAKT,
47 ATPPAGSRV,
48 FLQSGTAKSV,
49 CMDRGLTVFV,

50 VLLNWWRWRL,
51 GVFTGLTHI,
52 QMWKCLIRL,
53 IMTCMSADL,
54 ALAAYCLST,
55 VLSGKPAII,
56 FISGIQYLA,
57 YIMTCMSADL,
58 AIASLMAFTA,
59 GLAGAAIGSV,
60 MIGVLVGV,
61 VLPLAYISL,
62 SLGCIFFPL,
63 PLAYISLFL,
64 LMLFYQVWA,
65 NISIYNYFV,
66 NISVYNYFV,
67 FVWTHYYSV,
68 FLTWHRYHL,
69 LTWHRYHLL,
70 MLQEPSFSL,
71 SLPYWNFAT,
72 RLPEPQDVA,
73 VTQCLEVRV,
74 LLHTFTDAV,
75 NMVPFWPPV,
76 AVVGALLLV,
77 AVVAALLLV,
78 LLVAAIFGV,
79 SMDEANQPL,
80 VLPLAYISV,
81 SLGCIFFPV,
82 PLAYISLFV,

83 LLLFQQARV,
84 LMLFYQVWV,
85 LLPSSGPGV,
86 NLSIYNYFV,
87 NLSVYNYFV,
88 FLWTHYYSV,
89 SLKKTFLGV,
90 FLTWHRYHV,
91 MLQEPSFSV,
92 SLPYWNFAV,
93 ALGKNVCDV,
94 SLLISPNSV,
95 SLFSQWRVV,
96 TLGTLCNSV,
97 RLPEPQDVV,
98 VLQCLEVRV,
99 SLNSFRNTV,
100 SLDSFRNTV
101 FLNGTGGQV
102 VLLHTFTDV
103 ALVGALLLV
104 ALVAALLLV,
105 LLVALIFGV,
106 YLIRARRSV,
107 SMDEANQPV,
108 SLGCIFFPLL,
109 GMCCPDLSPV,
110 AACNQKILTV
111 FLTWHRYHLL,
112 SLHNLAHLFL
113 LLLVAAIFGV
114 LLVAAIFGVA,
115 ALIFGTASYL,

116 SMDEANQPLL,
 117 LLTDQYQCYA,
 118 SLGCIFFPLV,
 119 FLMLFYQVWV,
 120 ALCDQRVLIV,
 121 ALCNQKILTV,
 122 FLTWHRYHLV,
 123 SLHNLAHLFV,
 124 NLAHLFLNGV,
 125 NMVPPFWPPVV,
 126 ILVVAALLLV,
 127 LLVALIFGTV,
 128 ALIFGTASYV,
 129 SMDEANQPLV,
 130 LLTDQYQCIV,
 131 LLIQNIIQNDT,
 132 IIQNDTGFYTL,
 133 TLFNVTRNDTA
 134 LTLLSVTRNDV
 135 GLYTCQANNSA,
 136 ATVGIMIGVLV,
 137 GLVPPQHLIRV,
 138 GLAPPVHLIRV,
 139 GLAPPEHLIRV,
 140 ILIGVLVGV,
 141 YLIMVKCWMV,
 142 LLGRDSFEV,
 143 FMYSDFHFI,
 144 NMLSTVLGV
 145 SLENFRAYV,
 146 KMAELVHFV,
 147 KLAELVHFV
 148 VLIQRNPQV,

149 VLLGVVFGV,
150 SLISAVVGV,
151 YMIMVKBWMI,
152 YLIMVKBWMV,
153 KLWEELSVV,
154 AMBRWGLLV,
155 IJIGVLVGV,
156 ATVGIIJGV,
157 SJPPPGTRV,
158 LVFGIELJEV,
159 ILGFVFTL,
160 KIFGSLAFL,
161 YLQLVFGIEV,
162 MMNDQLMFL,
163 ALVLAGGFFL,
164 WLCAGALVL,
165 MVFELANSI,
166 RMMNDQLMFL,
167 LVLAGGFFL,
168 VLAGGFFLL,
169 LLHETDSAV,
170 LMYSLVHNL,
171 QLMFLERAFL,
172 LMFLERAFL,
173 KLGSGNDFEV,
174 LLQERGVAYI,
175 GMPEGDLVYV,
176 FLDELKAENI,
177 ALFDIESKV,

178 and GLPSIPVHPI.

179

1 3. A composition comprising an immunogenic peptide selected from
2 a group consisting of:

3 RVYPELPK,

4 TVSAELPK,

5 TVYAEPPK,

6 TINYTLWR,

7 LVHFLLLK,

8 SVFAHPRK,

9 KVLHHMVK,

10 RVCACPGR,

11 KMFCQLAK,

12 RAHSSHLK,

13 FVSNLATGR,

14 RLQLSNGNK,

15 RINGIPQQK,

16 KIRKYTMRK,

17 LVHFLLLKK,

18 SMLEVFEGK,

19 SSFSTTINK,

20 TSYVKVLHK,

21 VIFSKASEK,

22	GSVVGNWQK,
23	SSLPTTMNK,
24	SVLEVFEGK,
25	SSBMGGMNK,
26	SSCMGGMNK,
27	RTLTLFNVTK,
28	TISPLNTSYK,
29	STTINYTLWK,
30	ASSLPTTMNK,
31	KTYQGSYGFK,
32	VVRRBPHHEK,
33	GLAPPQHLIK,
34	NSSCMGGMNK,
35	SSBMGGMNRK,
36	RVCACPGRDK,
37	KTITVSAELPK,
38	TTITVYAEPPK,
39	PTISPSYTYR,
40	GLLGDNQVMPK,
41	MVELVHFLLK,
42	FSTTINYTLWR,

43 GLLGDNQIMPK,
 44 RLGFLHSGTAK,
 45 ALNKMFCQLAK,
 46 RVCACPGRDRR,
 47 LSQETFSDLWK,
 48 RAHSSHLKSKK,
 49 VTCTYSPALNK,
 50 GTRVRAMAIYK,
 51 STSRHKKLMFK,
 52 LAARNVLVK,
 53 MALESILRR,
 54 ISWLGLRSLR,
 55 GSGAFGTVYK,
 56 and ASPLDSTFYR.

1 4. A method of inducing a cytotoxic T cell response against a
 2 preselected antigen in a patient, the method comprising contacting cytotoxic T cells from
 3 the patient with a composition comprising an immunogenic peptide selected from the
 4 group consisting of:

5 RVYPELPK,
 6 TVSAELPK,
 7 TVYAEPPK,
 8 TINYTLWR,

9	LVHFLLLK,
10	SVFAHPRK,
11	KVLHHMVK,
12	RVCACPGR,
13	KMFCQLAK,
14	RAHSSHLK,
15	FVSNLATGR,
16	RLQLSNGNK,
17	RINGIPQQK,
18	KIRKYTMRK,
19	LVHFLLLKK,
20	SMLEVFEGK,
21	SSFSTTINK,
22	TSYVKVLHK,
23	VIFSKASEK,
24	GSVVGNWQK,
25	SSLPTTMNK,
26	SVLEVFEGK,
27	SSBMGGMNK,
28	SSCMGGMNK,
29	RTLTLFNVTK,

30 TISPLNTSYK,
31 STTINYTLWK,
32 ASSLPTTMNK,
33 KTYQGSYGFK,
34 VVRRBPHHEK,
35 GLAPPQHLIK,
36 NSSCMGGMNK,
37 SSBMGGMNRK,
38 RVCACPGRDK,
39 KTITVSAELPK,
40 TTITVYAEPPK,
41 PTISPSYTYR,
42 GLLGDNQVMPK,
43 MVELVHFLLLK,
44 FSTTINYTLWR,
45 GLLGDNQIMPK,
46 RLGFLHSGTAK,
47 ALNKMFCQLAK,
48 RVCACPGRDRR,
49 LSQETFSDLWK,
50 RAHSSHLKSKK,

51 VTCTYSPALNK,
52 GTRVRAMAIYK,
53 STSRHKKLMFK,
54 LAARNVLVK,
55 MALESILRR,
56 ISWLGLRSLR,
57 GSGAFGTVYK,
58 and ASPLDSTFYR.

59

1 5. A composition comprising an immunogenic peptide selected from
2 a group consisting of the peptides listed in Table 13.

1 6. A method of inducing a cytotoxic T cell response against a
2 preselected antigen in a patient, the method comprising contacting cytotoxic T cells from
3 the patient with a composition comprising an immunogenic peptide selected from the
4 group consisting of the peptides listed in Table 13.

5

HLA BINDING PEPTIDES AND THEIR USES

ABSTRACT OF THE DISCLOSURE

5 The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.

SF 175521 v1

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
220

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: the specification of which X is attached hereto or was filed on as Application No. and was amended on (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/205,713	March 4, 1994	pending

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Hector A. Alicea, Reg. No. 40,891	Joe Liebeschuetz, Reg. No. 37,505
Randolph T. Apple, Reg. No. 36,429	Jeffrey S. Mann, Reg. No. 42,837
Kevin L. Bastian, Reg. No. 34,774	Annette S. Parent, Reg. No. 42,058
Guy Chambers, Reg. No. 30,617	Steven W. Parmelee, Reg. No. 31,990
Karen B. Dow, Reg. No. 29,684	Brian W. Poor, Reg. No. 32,928
Gregory P. Einhorn, Reg. No. 38,440	Margaret A. Powers, Reg. No. 39,804
Susan K. Faris, Reg. No. 41,739	Jonathan Alan Quine, Reg. No. 41,261
M. Henry Heines, Reg. No. 28,219	Timothy L. Smith, Reg. No. 35,367
Laurence J. Hyman, Reg. No. 35,551	William M. Smith, Reg. No. 30,223
Tom Hunter, Reg. No. 38,498	Joseph P. Snyder, Reg. No. 39,381
Jeffrey J. King, Reg. No. 38,515	John R. Storella, Reg. No. 32,944
	Eugenia Garrett-Wackowski, Reg. No. 37,330
	Ellen Lauver Weber, Reg. No. 32,762
	Kenneth A. Weber, Reg. No. 31,667
Epimmune, Inc. Timothy J. Lithgow, M.D., J.D. Reg. No. 36,856	P. Ben Wang, Reg. No. 41,420

Send Correspondence to:	Direct Telephone Calls to: (Name, Reg. No., Telephone No.)
Ellen Lauver Weber TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834	Name: Ellen Lauver Weber Reg. No.: 32,762 Telephone: 415-576-0200

Full Name of Inventor 1:	Last Name: SETTE	First Name: ALESSANDRO	Middle Name or Initial:
Residence & Citizenship:	City: La Jolla	State/Foreign Country: CA	Country of Citizenship: Italy
Post Office Address:	Post Office Address: 5551 Linda Rosa Avenue	City: La Jolla	State/Country: CA Postal Code: 92037
Full Name of Inventor 2:	Last Name: SIDNEY	First Name: JOHN	Middle Name or Initial:
Residence & Citizenship:	City: La Jolla	State/Foreign Country: CA	Country of Citizenship: US
Post Office Address:	Post Office Address: 8541 D. Villa La Jolla Drive	City: La Jolla	State/Country: CA Postal Code: 92037
Full Name of Inventor 3:	Last Name: KAST	First Name: W.	Middle Name or Initial: MARTIN
Residence & Citizenship:	City: Leiden	State/Foreign Country: The Netherlands	Country of Citizenship: The Netherlands
Post Office Address:	Post Office Address: Maria Rutgersweg 106	City: Leiden	State/Country: Netherlands Postal Code: 2331 NX
Full Name of Inventor 4:	Last Name: SOUTHWOOD	First Name: SCOTT	Middle Name or Initial:
Residence & Citizenship:	City: Santee	State/Foreign Country: CA	Country of Citizenship: US
Post Office Address:	Post Office Address: 10679 Strathmore Dr.	City: Santee	State/Country: CA Postal Code: 92071
Full Name of Inventor 5:	Last Name:	First Name:	Middle Name or Initial:
Residence &	City:	State/Foreign Country:	Country of Citizenship:

Citizenship:			US	
Post Office Address:	Post Office Address:	City:	State/Country:	Postal Code:
Full Name of Inventor 6:	Last Name:	First Name:	Middle Name or Initial:	
Residence & Citizenship:	City:	State/Foreign Country:	Country of Citizenship:	
Post Office Address:	Post Office Address:	City:	State/Country:	Postal Code:

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 ALESSANDRO SETTE	Signature of Inventor 2 JOHN SIDNEY	Signature of Inventor 3 W. MARTIN KAST
Date	Date	Date
Signature of Inventor 4 SCOTT SOUTHWOOD	Signature of Inventor 5	Signature of Inventor 6
Date	Date	Date